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ABSTRACT 
 
Endothelial progenitor cells (EPC) are bone-marrow derived circulating cells 
participating in angiogenesis and vascular homeostasis. Reduced numbers 
of circulating EPC are observed in patients with various cardiovascular 
diseases and are related to an increased risk for future cardiovascular events 
and death. Little is known about functional changes.  The aim of this thesis 
was to study the function of EPC from patients with coronary artery disease 
(CAD) or with cardiovascular risk factors such as diabetes or advanced age. 
In particular, underlying molecular mechanisms were examined and potential 
therapeutic approaches were explored.  
CAD patients had reduced EPC numbers, which were correlated with 
increased plasma concentration of asymmetric dimethylarginine (ADMA), an 
endogenous nitric oxide synthase (NOS) inhibitor. In vitro, ADMA impaired 
EPC function which could be restored by statin treatment. In addition, EPC 
number and function decreased with age. Treatment of volunteers with 
growth hormone increased EPC levels and improved EPC function. Animal 
and in vitro studies showed the EPC increase to be directly mediated by the 
insulin-like growth factor 1 (IGF-1), which enhanced endothelial NOS 
expression of the EPC in a phosphoinositide-3-kinase/Akt dependent 
manner. Growth hormone-mediated increase in IGF-1 reversed age-related 
EPC dysfunction. Finally, function of EPC from patients with type II diabetes 
mellitus was analysed. Uncoupling of eNOS occurred within diabetic EPC 
and resulted in enhanced superoxide anion formation with subsequent EPC 
dysfunction. EPC dysfunction was protein kinase C-dependent, associated 
with reduced intracellular tetrahydrobiopterin (BH4) concentrations and 
reversible after exogenous BH4 treatment.  Impairment of EPC function is 
likely to contribute to the pathogenesis of vascular disease in diabetes 
mellitus. 
In conclusion, mechanisms underlying EPC dysfunction in various 
cardiovascular diseases were investigated and novel treatment approaches 
for dysfunctional EPC were explored. The knowledge may provide clues for 
the therapy and prevention of certain cardiovascular diseases. 
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Chapter I Endothelial progenitor cells (EPC)  
    in cardiovascular disease – 
    Introductory remarks 
 
1.1. Introduction 
 
This work described thesis has been performed within the last five years 
(2002-2007) at the Fraunhofer Institute for Toxicology and Experimental 
Medicine (Hannover, Germany), the Department of Cardiology of the Julius-
Maximilians-University (Würzburg, Germany) and the National Heart and 
Lung Institute of the Imperial College (London, U.K.). Within this timeframe 
many more experiments were performed and data were published (see 
Publications arising from the work in this thesis), than reported in the 
present PhD thesis. Here, I focused mainly on alterations of EPC number in 
function in cardiovascular disease. Troubleshooting experiments and 
experiments with a “negative” outcome were also performed, but are not 
reported in this thesis. 
 
A functional and intact endothelium plays a crucial role in the maintenance of 
vascular tone and structure. A major defence mechanism of endothelial cells 
to prevent vascular damage is endothelial nitric oxide synthase (eNOS), an 
enzyme that generates the vasoprotective molecule nitric oxide (NO) (1). 
eNOS is the predominant NOS isoform in the vasculature and responsible for 
most of the NO produced in this tissue (2). Endothelial injury and dysfunction 
are critical events in the pathogenesis of atherosclerosis and correlated with 
impaired NO bioavailability (3; 4). Understanding the mechanisms 
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responsible for the repair of endothelial lesions and restoration of endothelial 
function is likely to have important clinical implications. As resident 
endothelial cells infrequently proliferate in the vascular wall (5), other sources 
of cellular replenishment have been postulated as mechanisms for the repair 
of endothelial lesions. Bone-marrow derived endothelial progenitor cells 
(EPC) circulate in the blood and contribute to formation of new blood vessels 
and homeostasis of the vasculature, including replacement and repair (6; 7).  
 
In patients with coronary artery disease (CAD) circulating EPC are reduced 
(8-12). Likewise, bone marrow derived mononuclear cells from patients with 
CAD have diminished capacity to induce neovascularisation (13). Patients 
with reduced EPC levels are at increased risk for cardiovascular events and 
death (14; 15). Other studies suggest augmentation of circulating EPC may 
to result in improved coronary collateral development and improved vascular 
function (7; 16; 17; 17).  
 
Although EPC number is altered in many cardiovascular diseases, it can be 
expected that also EPC function plays an equal, probably more important 
role with regard to vascular homeostasis. Indeed, EPC need to be mobilised 
from the bone marrow, differentiate in the blood stream to more mature EPC, 
home and migrate to areas with ischemia and/or endothelial lesions, adhere, 
proliferate and incorporate into the lesion finally leading to endothelial 
restoration (reviewed in (18)). To test various EPC function, in vitro assays 
have been established previously to specifically test differentiation (see 
3.2.4.1. and 4.2.4.1.), migratory capacity (see 4.2.4.5.), proliferation (see 
3.2.4.3.), incorporation into vascular networks (see 3.2.4.4.) or eNOS activity 
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(see 3.2.5.). These assays including various fluorescence-activated- cell-
sorting (FACS)-based methods to measure EPC number, have been 
employed in the present thesis. It should be pointed out, that various other 
functional tests have been described in the literature, such as adhesion of 
EPC to mature endothelium (19) or measurements of EPC recruitment to 
vascular lesions after bone marrow transplantation of green-fluorescent 
protein (GFP)-overexpressing EPC (20). 
 
However, the underlying mechanisms of EPC dysfunction in various disease 
settings are far from understood. Mobilisation and differentiation of EPC is 
known to be modified by NO (21-23) and bone marrow-expressed eNOS is 
essential for the mobilisation of stem and progenitor cells in vivo (21). 
Endogenous NOS inhibitors, such as asymmetric dimethyl-L-arginine 
(ADMA), contribute to endothelial dysfunction and inhibition of angiogenesis 
in vivo (24; 25). ADMA is also a marker for cardiovascular risk and is 
correlated to the incidence of major adverse cardiovascular events or deaths 
(24; 26). Due to the important role of NO for EPC biology, it can be 
hypothesised that ADMA may be an important endogenous inhibitor of EPC 
mobilisation and function, thereby contributing to the pathogenesis of 
coronary artery disease (27). 
 
A further contributor to cardiovascular disease is advanced age (28). Indeed, 
cardiovascular disease is the leading cause of morbidity and mortality in 
industrial nations (29). Risk for cardiovascular disease increases with age 
and is associated with increased rates of complications and poorer clinical 
outcomes in older patients. Cardiovascular disease is predominant within the 
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elderly population, with approximately 85% of all deaths attributable to 
cardiovascular disease in the United States occurring in individuals more 
than 65 years of age (29). Previously increasing age has been associated 
with decreased number (30) and impaired function of EPC (31), which may 
facilitate atherosclerotic processes. Growth hormone regulated synthesis of  
the insulin-like growth factor-1 (IGF-1) which has been shown to exert 
various effects on cardiovascular function (32). Reduced IGF-1 levels are 
common in the elderly and are associated with an increased risk for ischemic 
heart disease (33). IGF-1 promotes survival and proliferation of resident 
cardiac stem cells (34), enhances migration, tube formation and 
angiogenesis of mature endothelial cells and leads to an increase in 
endothelial telomerase activity in cardiac tissue (35). IGF-1 transgenic mice 
display increased telomerase activity and preservation of cardiac resident 
stem cells (35). However, the effects of growth hormone and/or IGF-1 on 
EPC homeostasis, telomere activity and function are not known.  
 
A further risk factor involved in  the development of cardiovascular disease is 
diabetes mellitus (36; 37). Endothelial dysfunction as a first step in the 
pathogenesis of diabetes promotes arteriosclerosis (38). Reduced levels of 
EPC have been described in both type I and type II diabetic patients (10; 39). 
EPC recruitment for reendothelialisation after vascular injury is impaired in 
diabetes (40). These alterations are likely to be involved in the pathogenesis 
of vascular disease in diabetes (41). Likewise, a NO dysbalance plays a role 
in the pathophysiology of diabetes. Mechanistically, uncoupling of eNOS in 
blood vessels of diabetic patients leads to excessive superoxide anion 
production and diminishes NO availability (42; 43). Although eNOS is of 
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paramount importance for the regulation of mobilisation and function of EPC 
(21; 44), data about the role of eNOS uncoupling in diabetic EPC are not 
available. 
The aim of the present thesis was therefore to investigate number and 
function of EPC in patients with common cardiovascular risk factors, such as 
high ADMA plasma levels or presence of type II diabetes, as well as in 
patients with advanced age. Underlying mechanisms of EPC dysfunction in 
the various disease settings (ADMA, Chapter III; aging, Chapter IV; 
diabetes, Chapter V; see 1.1.; Fig. 1) were examined. In vitro and in vivo 
treatment concepts were developed for an improvement of EPC biology. 
Finally, experiments linking findings from Chapter III-V were performed 
(Chapter VI).  
1.2. Figure 1 
 
Effects of substances detrimental to EPC with regard to number and function are 
in part mediated by NO. A dysbalance between EPC mediated vascular repair and 
endothelial injury finally leads to endothelial dysfunction and 
development/progression of atherosclerosis (modified from (12). 
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Chapter II History of EPC research 
 
Vascularisation and revascularisation to ensure blood supply is an important 
mechanism for the survival of growing, injured, and ischemic tissues. More 
than ten years ago, it was believed that the sole mechanism for development 
of new vascular networks in the setting of growth or tissue ischemia was 
angiogenesis, resulting from vascular sprouting followed by vascular 
myogenesis (45). A complete paradigm shift occurred some years later, 
when various laboratories presented evidence that adult bone marrow 
contains a source of cells which can participate in postnatal vasculogenesis. 
Asahara et al. isolated putative endothelial cell progenitors from human 
peripheral blood (6). In vitro, these cells differentiated into mature endothelial 
cells and using in vivo models of ischemia, it was shown that EPC 
incorporated into sites of ongoing angiogenesis (6). These early findings 
suggested that EPC may be useful for augmenting vessel growth to ischemic 
tissues. A variety of further animal studies have now clearly demonstrated 
that bone marrow–derived cells play a role in physiological and pathological 
growth in the adult, both by augmenting angiogenesis through the secretion 
of angiogenic growth factors and by providing a rich source of progenitor 
cells that can circulate and differentiate into mature vascular endothelial cells. 
For instance, in animals with a genetic defect that inhibits a contribution of 
bone marrow–derived cells to vasculogenesis, the vasculogenic defect is 
completely reversed by transplantation of wild-type mobilised progenitor cells 
(46). These findings suggest that vasculogenesis observed in transplantation 
models is derived mainly from bone marrow–derived EPCs, although recent 
 21
studies suggest that “non-bone marrow” progenitor cells may be additional 
sources (47).  
EPC contribute to neovascularisation in various processes such as 
myocardial ischemia and infarction, limb ischemia, wound healing, 
atherosclerosis, endogenous endothelial repair, and tumour vascularisation 
(see (48) for review). Moreover, bone marrow–derived cells now have 
entered clinical medicine and are tentatively used to improve tissue 
neovascularisation and cardiac function after myocardial infarction or during 
heart failure (49-54), although many drawbacks and problems still exist that 
have to be overcome. 
Despite the recent success with EPC, the phenotypic characterisation of EPC 
remains highly controversial and a variety of different subtypes of EPC have 
been identified (18). The attempt to characterise accurately these cells has 
been confounded by the presence of other circulating mature endothelial 
cells and circulating EPC of various development stages. In strong contrast 
to EPC, circulating mature endothelial cells are mainly derived from sloughed 
off mature vascular endothelium and have a reduced ability to participate in 
postnatal vasculogenesis (55; 56). 
A further problem in the characterisation of EPC is the considerable overlap 
between proteins expressed on the surface of putative EPC and those 
expressed on cells of haematopoietic lineages, such as CD31 (57), CD34 
(58), and vascular endothelial growth factor receptor-2 (VEGFR-2, KDR) 
(59).  
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It appears that several distinct cell populations can qualify as EPCs based on 
their potential to enhance neovascularisation of ischemic areas. How these 
different types of cells are related to each other remains in part unclear. Cells 
are usually isolated and identified from peripheral blood or bone marrow. 
Often, mononuclear cells are selected for expression of either VEGFR2 or 
CD34, a marker known to be expressed on some haematopoietic stem cells 
as well as mature endothelial cells (15). Initially, isolated cells do not express 
endothelial markers such as von Willebrand factor (vWF) as do mature 
endothelial cells, but a characteristic feature of EPC is that in culture vWF 
expression and other similar markers (e.g. eNOS) appear under certain 
culture conditions (21; 60-63). In addition, numerous investigators have found 
that subpopulations of CD34+/VEGFR2+ cells can behave as EPCs. As 
discussed above, some mature endothelial cells can also co-express CD34 
and VEGFR-2. Therefore, the stem cell marker CD133 may be a more 
precise marker for defining subpopulations of cells that represent EPCs as 
this marker is not expressed on mature endothelial cells (64). CD133 is a 
five-transmembrane glycoprotein whose function is not well understood but is 
expressed on a population of cells with pluripotent haematopoietic stem cell 
properties (65). Cells with surface expression of CD34+, CD133+ or 
CD133+/VEGFR2+ have been reported to show clonogenic potential and to 
form CFU structures (66; 67). However, subsets of CD34+ cells that co-
express CD133 have an enhanced proliferative capacity and can give rise to 
endothelial colonies in culture (64; 68). CD133+/VEGFR2+ double positive 
cells have been found to play a role in endothelial repair (see (69) for review). 
A complete comparision between various EPC subtypes and their distinct 
functional properties, such as CFU formation, has never been performed. 
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This would be helpful to indentify most suited EPC types with potential use in 
clinical medicine, e.g. transplantation after myocardial infarction. There also 
exist multipotent adult progenitor cells, human bone marrow–derived adult 
progenitor cells that co-purify with mesenchymal stem cells, which have the 
ability to differentiate into multiple cell types. These CD34 /CD133+/ 
VEGFR2+ cells potentially represent a further subset of EPCs which 
participate in vasculogenesis (70).  
Some cells isolated from peripheral blood under endothelial culture 
conditions start proliferation and form colony forming units (CFU) early after 
cell seeding on fibronectin-coated dishes and are another EPC subtype 
(early outgrowth EPC; early CFU) (9). The endothelial lineage of these cells 
has been confirmed previously by immunocytochemical staining for von 
Willebrand factor, vascular endothelial growth factor receptor 2, and CD31 
(9). 
Finally, cells of monocytic lineage, as determined by the expression of the 
cell surface marker CD14, represent yet a further population of cells that may 
act as EPCs (71). CD14+ cells purified from peripheral blood mononuclear 
cells and cultured in endothelial growth media form adherent cells that have 
characteristics of endothelial cells, such as expression of vWF and VEGFR-
2, but also express CD45 (72). CD14+ EPC form spindle-shaped cells after 
several days in culture, take up acetylated LDL, and bind to Ulex europaeus 
agglutinin I (73). However, few of these cells express markers seen on 
mature endothelial cells, such as VE-cadherin, E-selectin, or CD34, whereas 
others are expressed (e.g. vWF;(62)). Most importantly, these cells improve 
neovascularisation and directly participate in vasculogenesis in vivo therefore 
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also qualify as an EPC subtype (72). In strong contrast, freshly isolated 
CD14+ cells that are not expanded in culture do not enhance angiogenesis. 
The “optimal” cell type has not been defined and it is highly likely that 
different subtypes of EPC have altered functional properties, leading to 
different effectiveness in different diseases.   
 
In the studies presented in the following (Chapter III-VI), number and 
function of various different subtypes of EPC (as discussed above), were 
investigated, including:  
- monocytic EPC 
- endothelial early outgrowth progenitor cells (endothelial CFU) and 
- CD34+/CD133+ cells 
- CD133+/VEGFR2+ cells. 
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Chapter III EPC in patients with coronary artery 
disease– Role of the endogenous NO 
synthase inhibitor asymmetric 
dimethylarginine (ADMA)  
 
3.1. Background of the study 
 
As mobilisation and differentiation of EPC is modified by NO (17; 21; 22), and 
bone marrow-expressed eNOS is essential for the mobilisation of stem and 
progenitor cells in vivo (17; 21), endogenous NO synthase inhibitors, such as 
ADMA, may contribute to EPC dysfunction.  
Under normal conditions, the amino acid L-arginine is the substrate for 
endothelial NO synthesis (74). However, the endothelium is also capable of 
producing methylated amino acids such as ADMA, which are able to out-
compete L-arginine as a substrate for eNOS, finally leading to endothelial 
dysfunction (75-77). The molecular structure of L-arginine, ADMA and other 
endogenous methylaginines, such as SDMA and L-NMMA are shown in 
3.5.1. (Fig. 1A). In addition, the synthesis and metabolism of ADMA and 
related compounds is described in 3.5.1. (Fig. 1B). Circulating levels of 
ADMA are elevated in patients with cardiovascular risk factors, are 
associated with the presence of endothelial dysfunction (75; 78; 79) and 
independently predict future cardiovascular risk (26). 
Therefore, the relationship between plasma ADMA concentrations and the 
number of circulating progenitor cells was analysed in patients with stable 
angina admitted for coronary angiography. Additionally, the effects of ADMA 
on differentiation and functional capacity of cultured EPC from healthy donors 
 26
were studied. The main hypothesis was that ADMA may be an important 
endogenous inhibitor of EPC mobilisation and function. 
 
3.2. Methods 
 
3.2.1. Study subjects 
 
Approval from the ethical committee of the University of Würzburg was 
obtained, as was informed written consent from patients. Patients admitted to 
hospital because of stable angina (49 men) aged 39 to 81 years (mean age 
66.1 ± 1.1 years) were enrolled. All patients underwent cardiac 
catheterisation and CAD was excluded (CAD 0) or quantified by the number 
of coronary arteries involved (CAD 1-3). For a stenosis to qualify, the luminal 
diameter of the coronary vessel had to be reduced by at least 50%. Patient 
characteristics are shown in Table 1. We selected n=20 patients for each 
group (CAD0-3).   
  
3.2.2. Measurement of ADMA in plasma samples 
 
Blood (5 ml) was drawn from the antecubital vein of patients using syringes 
containing ethylenediaminetetraacetic acid (EDTA) and immediately put on 
ice. Blood samples were centrifuged at 1500 g and 4 °C for 15 min. The 
plasma obtained was used immediately or stored at –80 °C until further 
analysis. Ultrafiltrates (approx. 0.7-0.8 ml) from 1-ml aliquots of plasma 
samples were obtained by centrifugation at 7500 g and 20 °C for 20 min 
using the Amicon Ultra Millipore ultrafiltration cartridges. For detection and 
measurement of ADMA a gas chromatography-tandem mass spectrometry 
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method was used (80). The measurements were performed on a triple-stage 
quadruple mass spectrometer Thermo Quest TSQ 7000 (Finnigan MAT, San 
Jose, CA) directly interfaced with a Trace 2000 series gas chromatograph 
equipped with an auto sampler AS 2000 (CE Instruments, Austin, TX). The 
gas chromatograph was equipped with a fused-silica capillary column Optima 
17 (30 m x 0.25 mm I.D., 0.25 µm film thickness) from Macherey-Nagel 
(Düren, Germany). Synthetic ADMA served as the internal standard. These 
measurements were performed together with the Department of Clinical 
Pharmacology (Dr. Tsikas) in Hannover, Germany. 
 
3.2.3. Isolation of peripheral blood mononuclear cells (PBMCs) 
 
PBMCs were isolated by Ficoll® density centrifugation as described (9).  For 
in-vitro assays PBMCs were harvested by blood withdrawal or leukapheresis 
(Cobe Spectra device, Gombro, Germany) of healthy volunteers (n=5). 
Leukapheresis procedures were performed by the Department of Transfusion 
Medicine in Würzburg, Germany. 
 
3.2.4. Analysis of progenitor cells  
 
Various assays were used to determine the amount, differentiation and 
function of EPC:  
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3.2.4.1. EPC cell culture assay 
 
2 x 105 PBMCs were cultured on fibronectin-precoated 8-well chamber slides 
(Lab-Tek, Germany) in EBM-2 culture medium supplemented with EGM 
SingleQuots (Cambrex, Belgium) for 4 days. To exclude contamination with 
mature circulating endothelial cells, culture supernatant was removed 8 h 
after initial seeding and placed to fibronectin-precoated chamber slides. After 
dilution of 1,1'-dioctadecyl-3,3,3',3-tetramethyl-indocarbocyanine perchlorate 
labelled acetylated LDL (dil-acLDL; Molecular Probes, Eugene, USA) and 
FITC-conjugated lectin from Ulex europaeus (UEA-1; Sigma, Germany) in 
serum-free EBM2 media, cells were washed twice and incubated for 4 h at 
37 °C in EBM2 medium containing 10 µg/ml dil-acLDL and 10 µg/ml UEA-1. 
After washing, cells were observed by fluorescence microscopy. Only double 
positive (dil-acLDL and UEA-1) cells were counted in at least 8 independent 
randomly selected high-power fields. 
 
3.2.4.2. Detection of CD34+/CD133+ cells 
 
PBMCs were isolated by Ficoll® density centrifugation as described above 
(3.2.3.). Then, a volume of 60 µL (about 1x105 PBMCs) with appropriate 
amounts of fluorescein isothyocyanate (FITC)–labelled monoclonal mouse 
antihuman CD34 and allophycocyanin (APC)-labelled monoclonal mouse 
antihuman CD133/2 (293C3) antibody (Miltenyi Biotec, Germany) was 
incubated for 10 min at 6 °C. In parallel experiments, appropriate isotype 
controls (FITC-conjugated mouse IgG2a monoclonal IG and APC-conjugated 
mouse IgG2b monoclonal IG) were added. At least 20,000 cells were 
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acquired using a FACSCalibur cytometer (Becton Dickinson). The number of 
progenitor cells was expressed as a percentage of all PBMCs.  
 
3.2.4.3. Determination of endothelial colony forming units  
 
PBMCs were isolated by Ficoll® density gradient centrifugation and 5x106 
cells from leukapheresis donors were plated on fibronectin-coated 6-well 
plates in EndoCult™ medium (StemCell Technologies, USA) according to the 
manufacturer’s instructions. In the patient studies, 5x106 PBMCs were 
cultured on fibronectin-coated 12-well plates. After 48 h, non-adherent cells 
were collected and plated in replicate fibronectin-coated 24-well plates. 
Colonies were evaluated and quantified three days later. A colony was 
defined as a central core of "round" cells with more elongated "sprouting 
cells" at the periphery and are referred to as early outgrowth colony forming 
unit - endothelial cell (9). The endothelial lineage of these cells has been 
confirmed previously by immunocytochemical staining for von Willebrand 
factor, vascular endothelial growth factor receptor 2, and CD31 (9). 
 
3.2.4.4. Incorporation into tube like structures 
 
Incorporation of EPC during endothelial tube formation was measured as 
follows; dil-acLDL pre-labelled EPC (2 x 104 cells) were mixed with human 
umbilical vein endothelial cells (HUVECs) (4 x 104) on an 8-well glass slide 
precoated with 200 µL Matrigel (BD Bioscience, Germany) in 500 µL EBM-2 
medium with supplements (Cambrex, Belgium) with the addition of 0, 1.0, 5.0 
or 10.0 µmol ADMA. Further, the 10 µmol group was co-treated with 
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rosuvastatin (10 µmol). The concentration of rosuvastatin was based on a 
previous in vitro study (81). After 8 h of incubation in 5% CO2 humidified 
atmosphere at 37 °C, cells were examined under a fluorescence microscope. 
The amount of incorporated dil-ac-LDL labelled EPC in formed endothelial 
tubes was determined. In blinded experiments at least 8 randomly selected 
high-power fields were examined. 
 
3.2.5. Detection of eNOS activity in EPC  
 
Cultured EPC were pre-treated with 0, 1.0, 5.0 or 10.0 µmol ADMA, as well 
as ADMA (10 µmol) + rosuvastatin (10 µmol) for 24h. EPC were then 
incubated at 37 °C with  5 mmol L-[guanidino-15N2]arginine for 8 h. Then, 
supernatant was removed and eNOS activity was determined by assessing 
the conversion of L-[guanidino-15N2]arginine to 15N-nitrate with gas 
chromatography-mass spectrometry, according to a previously described 
method (32; 82). These measurements were performed together (Dr. Tsikas) 
with the department of Clinical Pharmacology in Hannover, Germany. 
 
3.2.6. Statistical analysis  
 
Data presented are expressed as mean ± SEM. Statistical analysis was 
performed by one-way ANOVA followed by multiple comparisons using 
Fisher’s protected least-significant difference test. To analyse relationships 
between variables simple, polynomial and multivariate regression analyses 
were performed. Statistical analysis was performed using StatView 5.0 
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statistic program (Abacus Concepts, Berkley, CA, USA). Statistical 
significance was assumed at p<0.05. 
 
3.3. Results 
 
3.3.1. Clinical study 
 
First, the relation between plasma concentrations of ADMA and the number 
of circulating progenitor cells was analysed. Patients were divided in 4 
groups; patients in whom coronary lesions were < 50% of diameter (CAD0; 
controls) and patients with 1, 2 or 3 involved coronary vessels (CAD1-3). 
There was no statistical difference in age among the different patient groups 
as shown in 3.4.1. (Table 1). Total cholesterol levels were higher in CAD 
patients (CAD0: 187.1 ± 7.8 mg/dl vs. CAD2: 214.7  ± 10.8 mg/dl; P<0.05; 
3.4.1. (Table 1)), but not correlated to the severity of disease (see 3.4.1. 
(Table 1)) or the amount of circulating CD133+/CD34+ progenitor cells (r= -
0.01; p=not significant). Circulating CD133+/CD34+ progenitor cells correlated 
well with endothelial CFU (r=0.83, p<0.0001). ADMA plasma concentrations 
in patients increased with the severity of CAD (CAD0: 0.47 ± 0.02 µmol/l vs. 
CAD3: 0.58 ± 0.02 µmol/l; P<0.001; 3.4.1. (Table 1), 3.5.2. (Fig. 2A)). There 
was an inverse correlation between ADMA plasma levels and the amount of 
CD133+/CD34+ progenitor cells (r=-0.69, P<0.0001; 3.5.2. (Fig. 2B)) or 
endothelial CFU (r=-0.75, p<0.0001; 3.5.2. (Fig. 2D)) in isolated PBMCs of 
patients, which were reduced by 77.3 % and 50.3 % in patients with 3-vessel-
disease (CD133+/CD34+ cells: CAD0: 0.22 ± 0.03 % vs. CAD3: 0.05 ± 0.01 
%, P<0.0001. CFU: CAD0: 16.7 ± 1.2 colonies / well vs. CAD3: 8.3 ± 0.7 
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colonies / well, p<0.0001; see 3.4.1. (Table 1)). Diabetes was correlated to 
the number of vessels with CAD (p≤0.004), whereas hypertension was not 
(3.4.1. (Table 1)). Patients with severe CAD were more commonly treated 
with a statin (p<0.001) or nitrates (p<0.05), whereas treatment with other 
drugs was not different between the groups (3.4.1. (Table 1)). 
 
Stepwise multivariate regression analysis identified ADMA (standardised 
coefficient -0.51, p<0.0001) and CAD (standardised coefficient -0.43, p<0.01) 
to relate independently to the number of circulating CD34+/CD133+ progenitor 
cells. In this analysis the following factors were not significant predictors: age, 
plasma creatinine, leukocytes, haemoglobin, CRP, hypertension, diabetes 
mellitus, drug treatment (aspirin, clopidogrel, ACE inhibitors, ACE receptor 
blockers, beta-blockers, statins, nitrates), total cholesterol, LDL and HDL. In 
similar analysis only ADMA significantly predicted endothelial CFU 
(standardised coefficient -0.67, p<0.0001). 
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3.3.2. ADMA inhibits differentiation and function of EPC in vitro 
 
ADMA reduced the amount of adherent dil-acLDL/UEA-1 double positive 
cells after 4 days in culture to 37 % ± 4 % (p<0.0001; n=5; 3.5.3. (Fig. 3)) in a 
concentration-dependent manner. The number of endothelial CFUs formed 
after 5 days of cell culture was repressed after treatment with increasing 
concentrations of ADMA (3.5.4. (Fig. 4A)). Co-treatment with the HMG CoA 
reductase inhibitor rosuvastatin (10 µM, 24h) normalised the amount of 
formed CFU. ADMA treatment resulted in repression of the colony sizes to 29 
% ± 9 % (p<0.0001; n=5), whereas rosuvastatin attenuated the effects of 
ADMA (3.5.4. (Fig. 4B)). The capability to incorporate into tube-like structures 
in co-culture experiments with HUVECs was repressed to 27 % ± 11 % 
(p<0.001; n=5)  of controls after 24h of pre-incubation of EPC with ADMA (10 
µM). This inhibitory action was reversed with concomitant rosuvastatin 
treatment (3.5.5. (Fig. 5)). Upon ADMA treatment eNOS activity was reduced 
to 64 % ± 6 % (p<0.05; n=5) of controls, whereas co-treatment with 
rosuvastatin (10 µM, 24h) normalised eNOS activity (3.5.6. (Fig. 6)).   
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3.4. Tables 
 
3.4.1. Table 1 Patient characteristics, ADMA and EPC 
measurements 
 
  controls  CAD1 CAD2 CAD3  P value 
  (n=20) (n=20) (n=20) (n=20) 
CAD0 vs. 
CAD3 
            
Age (years) 64.6 ± 1.8 63.7 ± 1.0 66.7 ± 2.0 69.5 ± 3.0 0.11 
Males (%) 55.0 60.0 65.0 65.0 0.75 
CD34+ / CD133+ (%) 0.22 ± 0.03 0.18 ± 0.04 0.11 ± 0.02 0.05 ± 0.01 < 0.0001 
CFU (number / well) 16.7 ± 1.2 16.8 ± 2.1 10.7 ± 1.2 8.3 ± 0.2 < 0.0001 
ADMA (µmol/l) 0.47 ± 0.02 0.45 ± 0.02 0.51 ± 0.03 0.58 ± 0.02 < 0.001 
Hypertension (%) 70 65 90 85 0.26 
Diabetes (%) 5 30 25 35 0.004 
Medication* (%)           
    Aspirin 75 90 85 75 1.00 
    Clopidogrel 15 25 20 10 0.68 
    ACE inhibitors /         
ARB 50 65 60 55 0.75 
    Beta-Blocker 50 55 70 75 0.11 
    Statin 20 50 55 75 < 0.001 
    Nitrates 0 30 15 30 ≤ 0.015 
Other laboratory data:      
Creatinine (mg/dl) 0.84 ± 0.06 0.92 ± 0.04 0.99 ± 0.06 0.98 ± 0.06 0.08 
Cholesterol (mg/dl) 187.1 ± 7.8 204.6 ± 9.9 214.7 ± 10.8 180.9 ± 10.5 ≤ 0.048 † 
LDL (mg/dl) 105.9 ± 6.9 118.1 ± 8.2  126.2 ± 9.3 96.5 ± 7.1 0.39 
HDL (mg/dl) 54.4 ± 3.2 50.9 ± 3.4 51.6 ± 3.5 48.6 ± 3.7 0.24 
Haemoglobin (g/dl) 14.3 ± 0.4 14.1 ± 0.4 14.2 ± 0.3 13.3 ± 0.3 0.07 
CRP (mg/dl) 0.84 ± 0.23 0.60 ± 0.16 0.52 ± 0.10 0.83 ± 0.20 0.97 
Leukocytes (103/mm3) 6.9 ± 0.4 7.0 ± 0.4 7.9 ± 0.5 7.9 ± 0.6 0.15 
Values are means ± SEM.   
ADMA, asymmetric dimethylarginine; ARB, angiotensin receptor blockers; CAD, coronary  
artery disease; CAD0-3, number of involved major coronary vessels; CRP, C-reactive 
protein   
*Medication at admission to hospital; †P<0.05 versus CAD2 
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3.5. Figures 
 
3.5.1. Figure 1 
 
 
Molecular structure, synthesis and metabolism of ADMA and related 
compounds 
A) Molecular structure of L-arginine, asymmetric dimethylarginine (ADMA), 
symmetric dimethylarginine (SDMA) and L-monomethylarginine (L-NMMA) is 
shown. B) L-arginine is metabolised by protein arginine methyltransferases (PRMT) 
to methylated L-arginine, that after proteolysis forms the compounds ADMA, SDMA 
and L-NMMA. Like ADMA, MMA also directly inhibits nitric oxide synthases, whereas 
SDMA has no direct effect on this enzyme. Because physiological concentrations of 
ADMA are 10-fold higher than those of L-NMMA, ADMA can be regarded as the 
predominant endogenous inhibitor of NO biosynthesis. Both ADMA and SDMA are 
eliminated from the body by urinary excretion. In contrast, the most important 
metabolic pathway for ADMA is degradation by the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH), which converts ADMA into dimethylamine (DMA) 
and citrulline.  
L-arginine 
L-arginine 
CH3
PRMT 
proteolysis 
ADMA SDMA L-NMMA 
DDAH DDAH 
urine citrullin + 
monomethylamine 
 
A 
B 
citrullin + 
dimethylamine  
(DMA) 
 36
3.5.2. Figure 2 
 
 
Inverse correlation of plasma ADMA and progenitor cells in patients with 
coronary artery disease 
ADMA plasma levels (A) and circulating CD34+/CD133+ progenitor cells (C) in 
patients admitted to coronary angiography. CAD0= no coronary artery disease, 
n=20; CAD1= 1 vessel disease, n=20; CAD2= 2-vessel disease, n=20; CAD3= 3-
vessel disease, n=20. (B) Correlation between circulating CD34+/CD133+ progenitor 
cells or endothelial colony forming units (CFU) (D) with the concentration of plasma 
ADMA levels in patients with different severity of coronary artery disease (see 
3.4.1.).   
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3.5.3. Figure 3 
 
 
 
Inhibition of endothelial progenitor cell formation by ADMA.  
Adherent dil-ac-LDL / UEA-1-FITC double positive cells after treatment of PBMCs 
with increasing concentrations (1-10 µmol) of ADMA and ADMA + rosuvastatin (10 
µM) for 4 days (each n=5).  Cells were counted in at least 8 independent randomly 
selected high-power fields. Results are given as mean ± SEM. 
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3.5.4. Figure 4 
 
 
ADMA reduces amount and size of colony forming units.  
Amount (A) and size (B) of colony forming units after treatment of PBMCs with 
increasing concentrations of ADMA and ADMA + rosuvastatin (10µM). Each group 
n=5. Results are given as mean ± SEM. 
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3.5.5. Figure 5 
 
 
ADMA inhibits incorporation of EPC in tube-like structures.  
Incorporation of EPC (labeled with dil-ac-LDL; red) in forming endothelial tubes from 
HUVECs (labeled with UEA1-FITC; green) after treatment with increasing 
concentrations of ADMA or ADMA + rosuvastatin (10 µM). Each group n=5. At least 
8 randomly selected high-power fields per experiment were examined. Results are 
given as mean ± SEM. 
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3.5.6. Figure 6 
 
 
ADMA inhibits eNOS activity in EPC.  
eNOS activity was determined in EPC cell culture supernatants by assessing the 
conversion of L-[guanidino-15N2]arginine to 15N-nitrate with gas 
chromatography/mass spectrometry. The 15N-nitrate/14N-nitrate ratio is shown. 
Each n=5. Results are given as mean ± SEM. 
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3.6. Discussion 
The data identify an inverse correlation between the number of circulating 
progenitor cells, the severity of coronary heart disease and ADMA plasma 
levels in patients admitted to hospital because of stable angina. In-vitro 
studies extend and support these clinical observations, as ADMA markedly 
repressed EPC differentiation and function. It can be assumed that the 
detrimental effects of ADMA on EPC function were mediated by reduced 
eNOS activity. The role of eNOS for EPC function was investigated in more 
detail and results will be presented later in this thesis (see Chapter IV). 
Indeed, others and our group have shown that eNOS derived NO plays a key 
role in the process of EPC mobilisation and differentiation (17; 21; 22) as well 
as angiogenesis (25). eNOS expression and activity in vitro and in vivo can 
be increased by statins (22; 81). In line with these findings, the HMG CoA 
reductase inhibitor rosuvastatin normalised eNOS activity in ADMA treated 
EPC, and reversed the inhibitory effects of ADMA on EPC differentiation and 
function.  
 
ApoE-deficient hypercholesterolemic mice display increased plasma ADMA 
levels and impaired angiogenesis (25). After adding ADMA directly to a 
subcutaneously implanted disk angiogenesis system, inhibition of basal and 
fibroblast growth factor-induced angiogenesis was observed in a dose-
dependent manner, showing that ADMA is an endogenous inhibitor of 
angiogenesis (25). In close relation with findings of this thesis, recent results 
from others have demonstrated that EPC play a pivotal role in 
neoangiogenesis (reviewed in (83)). Thus, ADMA mediated impairment of 
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EPC may explain, at least in part, reduced angiogenesis as observed by the 
impaired proliferation capacity of ADMA-treated CFUs in this study. 
Neovascularisation is impaired in diabetes, and EPC from diabetic patients 
exhibit decreased proliferation capacity, adhesion and incorporation into 
vascular structures (10). The close association between CAD and diabetes 
(84) as well as increased ADMA levels in this study cohort may suggest a 
contribution of ADMA-mediated reduction of circulating EPC and their 
function to CAD progression, especially in diabetes. It was therefore a further 
aim of this thesis to investigate the underlying molecular mechanisms in 
diabetes-related EPC dysfunction (see Chapter V). Interestingly, although 
total cholesterol concentrations were higher in our cohort of CAD patients, 
there was no significant correlation with the severity of CAD or the amount of 
circulating progenitor cells. Multivariate regression analyses demonstrated 
ADMA to be the strongest predictor of circulating progenitor cells (both 
CD34+/CD133+ cells and endothelial CFU) independently of disease (e.g. 
diabetes), basic lab parameters and treatment status, all of which have 
previously been shown to regulate EPC (10; 30; 44; 85; 86). Although 
increasing age was previously reported to be correlated with reduced EPC 
levels in patients with CAD (30), this was not seen in our study probably due 
to the minimal variation of age among the patients. We therefore also 
investigated EPC number and function in subjects with greater differences in 
age. These results will be presented later in this thesis (see Chapter IV). 
 
This part of the study identifies enhanced ADMA concentrations in patients 
with CAD as a predominant repressor of circulating progenitor cells in 
humans. The in vitro data further support a mechanistic link between 
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increased ADMA levels and decreased EPC function, although it cannot be 
completely ruled out that this was, in part, explainable by co-correlation as 
both ADMA and EPC levels are related to CAD (87).  
 
Our findings with the beneficial effects of HMG CoA reductase inhibitors on 
EPC need further discussion; indeed, HMG CoA reductase inhibitors are 
known to increase EPC mobilisation and function (22; 88; 89). Statin 
treatment of patients with stable CAD for 4 weeks led to a 3-fold increase in 
circulating progenitor cells (88). This treatment also augmented the migratory 
capacity of progenitor cells.  Likewise, statins increase EPC level after 
myocardial infarction (17). Some statins may also reduce ADMA plasma 
concentrations. One study has examined the effects of rosuvastatin on 
plasma levels of ADMA in patients with hypercholesterolemia were 
investigated in a multicenter, randomised, double-blind, placebo-controlled 
trial (90). Treatment for 6 weeks resulted in significant reductions of ADMA 
plasma levels and increased flow-mediated vasodilatation (90). In contrast, 
treatment with either simvastatin or atorvastatin did not reduce plasma ADMA 
levels, suggesting that the ADMA lowering effect may be specific for 
rosuvastatin (91), although more and larger studies are clearly needed for 
conclusive evidence. In the present study exposure to rosuvastatin 
normalised EPC differentiation and function. As patients suffering from CAD 
have reduced numbers, colony-forming capacity and migratory response of 
EPC, rosuvastatin may be an interesting drug both for quantitative and 
qualitative improvement of EPC in patients with cardiovascular disease, as 
previously suggested (89). There may be ADMA-dependent and -
independent effects of statins. It has been described that there may be class-
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effects of different statins on various end-points. For instance, rosuvastatin, 
but not simvastatin provides end-organ protection in stroke-prone rats (92). 
This was mediated by anti-inflammatory effects especially of rosuvastatin, 
and indeed it has been shown that the effects of various statins to modulate 
inflammatory reactions differ among the members of this class of drugs (93). 
In addition, rosuvastatin strongly increases eNOS expression in endothelial 
cells and protects mice from ischemic stroke (81). Antiinflammatory 
properties as well as eNOS inducing effects may explain the potent vascular 
protective effects of rosuvastatin. However, future studies needs to be 
performed to establish which statins is superior in improving EPC 
mobilisation, function and ultimately cardiovascular outcome.  
 
Statin treatment in rats with heart failure after myocardial infarction improves 
left ventricular remodelling and cardiac function (94). In contrast to that 
animal studies, rosuvastatin did not reduce the primary outcome or the 
number of deaths from any cause in older patients with systolic heart failure, 
although the drug did reduce the number of cardiovascular hospitalizations 
(95). The reason for this negative outcome is not clear, but the used 
treatment dose or treated patient population (older heart failure patients) may 
explain this. It could be that there would have been preventive effects if a 
higher dose had been used or a younger patient population had been 
treated.    
The present investigation suggests that improved EPC function by statins 
might contribute vasoprotection. Indeed, in patients with acute coronary 
syndrome intensive lipid-lowering statin regimen provides greater protection 
against death or major cardiovascular events (96). Development of novel 
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drugs, which effectively reduce ADMA levels, could lead into a novel 
therapeutic concept in the prevention and treatment of atherosclerosis based 
on improved mobilisation and function of EPC (27). On the other hand, there 
are conditions (e.g. diabetes) where eNOS, which normally produced 
vasoprotective amount of NO, becomes uncoupled to form toxic amounts of 
reactive oxygen species (Chapter V). Here, it may be that eNOS inhibition by 
increased levels of ADMA may protect the endothelium from exaggerated 
ROS levels (discussed in Chapter VI). 
 
3.7. Limitations of the study 
 
A relatively high dose of rosuvastatin was used in the in-vitro experiments. 
However, this concentration was based on multiple previous reports 
demonstrating that in vitro higher concentrations than in vivo are needed to 
demonstrate pleiotropic effects of statins, especially when modulation of 
eNOS activity is assessed (81; 97; 98). It needs to be shown whether lower 
levels of statins would exert beneficial effects on ADMA-mediated EPC 
dysfunction.  In addition, the concentrations of ADMA used in vitro were 
about 10-fold higher than plasma levels of patients. However, systemic 
ADMA levels in general appear to be lower compared with concentrations 
achieved in tissues (99). Therefore, the ADMA concentrations used in the in-
vitro assays are likely to reflect levels in local target tissues.   
 
In the patient cohort investigated, there was a significant positive correlation 
between CD34+/CD133+ cells and endothelial CFU, which have been shown 
to express vWF, VEGFR-2, and CD31. ADMA repressed both CD34+/CD133+ 
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cells and endothelial CFU, which supports the view that not only 
haematopoietic and EPC but also other progenitor cell types may be inhibited 
by high ADMA plasma levels.  Whether this inhibitory action is mediated 
directly in the bone marrow or within the plasma remains to be investigated in 
the future. 
 
In the present study more patients with the diagnosis of CAD were being 
treated with statins at the time of admission to hospital, when compared with 
patients without CAD (p=<0.001; 3.4.1. (Table 1)). Although statins increase 
the number of circulating EPC (22; 88), this was not observed in this study 
cohort. There are two possible reasons: First, dose dependent effects of 
statin treatment regarding the amount of mobilised EPC are currently not 
known. Higher doses of certain statins might result in stronger improvement 
of EPC mobilisation and function. It is likely, that if patients with severe 
coronary artery disease were not being treated with statins, EPC levels could 
be even lower. Second, the inhibitory effects of ADMA may be far stronger 
compared with statin effects. This should to be investigated in future studies. 
 
Data on this part of the thesis have recently been published (100). 
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Chapter IV EPC in advanced age – role of growth 
hormone and IGF-1 
 
 
4.1. Background of the study 
Endothelial injury and dysfunction are critical events in the pathogenesis of 
atherosclerosis. Increasing age is associated with decreased number (30) 
and impaired function of EPC (31), which may facilitate atherosclerotic 
processes. Regulation of EPC mobilisation, differentiation and function is 
complex, but specific growth hormones and cytokines are explicitly involved 
(11). IGF-1 enhances migration, tube formation and angiogenesis of mature 
endothelial cells (101) and increases telomerase activity (35). The effects of 
IGF-1 on endothelial cells are mediated at least in part via up regulation of 
eNOS expression (102). Low serum IGF-1 levels, common in the elderly, are 
associated with an increased risk for ischemic heart disease (33). Restoration 
of IGF-1 in elderly individuals by growth hormone therapy may have 
significant beneficial health effects (103). In growth hormone deficient 
patients replacement therapy attenuates the increased tendency to develop 
endothelial dysfunction and severe atherosclerosis (104). 
The effects of IGF-1 on EPC homeostasis and function are not known. 
Therefore, we investigated whether augmented IGF-1 levels in response to 
growth hormone treatment may restore the age-dependent decline in EPC 
levels and function in mice and humans. Ex vivo we tested, whether IGF-1 
treatment of EPC of aged individuals would restore function and attenuate 
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cellular senescence. In vitro studies were undertaken to identify underlying 
molecular mechanisms.  
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4.2. Methods 
 
4.2.1. Clinical study 
 
The ethical committees of the Universities of Hannover and Würzburg 
approved the study. Written informed consent was obtained from the 
volunteers. The clinical trial has been registered at www.ClinicalTrials.gov 
(NCT00470002). Sixteen healthy middle-aged male volunteers between 50 
and 69 years (mean age 57.4 ± 1.4 years) were enrolled in the recombinant 
human growth hormone (GH) treatment group. This was a non-randomized 
single-centre pilot trial. For comparison, twelve aged male individuals (mean 
age 74.1 ± 0.9 years) and ten healthy young male volunteers aged 23 to 31 
years (mean age 27.5 ± 0.9 years) were selected. None of the young or 
middle-aged (GH study group) study subjects smoked or were under drug 
treatment. Subjects within the treatment group with a history or sign of 
hepatic, renal, cardiac, endocrine, metabolic, or malignant diseases were 
excluded. The GH study group received a fixed dose of 0.4 mg GH 
(Pharmacia, Karlsruhe, Germany) subcutaneously per day in the evening for 
10 days. All measurements were performed directly before and after the 10 
day treatment. This clinical trial was performed together with the Department 
of Clinical Pharmacology (Prof. Dr. D. Stichtenoth; I. Klink) in Hannover, 
Germany. 
 
4.2.2. Measurement of IGF-1 and basic blood parameters 
 
Blood (10 ml) was drawn from the antecubital vein of patients using syringes 
containing ethylenediaminetetraacetic acid (EDTA) and immediately put on 
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ice. Blood samples were centrifuged at 1500 g and 4 °C for 15 min. The 
plasma obtained was used immediately or stored at –80 °C until further 
analysis. IGF-1 levels were determined using a commercially available IGF-1 
detection kit according to the manufacturer’s recommendation (human IGF-1: 
Nichols Institute Diagnostics, San Clemente, USA; mouse IGF-1: Mediagnost 
IGF-1, Reutlingen, Germany). White and red blood cell counts were 
determined by standardised techniques (this was done at the Medical School 
Hannover). 
 
 
4.2.3. Isolation of peripheral blood mononuclear cells (PBMCs) 
and CD34+, CD117+, CD133+ and CD133+/VEGFR2+ progenitors 
 
PBMCs were isolated by Ficoll® density centrifugation. For in vitro assays 
PBMCs were harvested by leukapheresis (Cobe Spectra device, Gombro, 
Germany) of healthy volunteers (n=5). A portion of PBMCs was incubated 
with an anti-CD34, anti-CD117 or anti-CD133 antibody conjugated to 
magnetic microbeads (Miltenyi, Germany) and then processed using 
magnetic affinity cell sorting (MACS) according to the manufacturer’s 
instructions (Miltenyi, Germany). To isolate CD133+/VEGFR2+ EPC, 
leukapheresis derived cells were first labelled with an APC-coupled 
monoclonal mouse antihuman CD133 antibody (Miltenyi Biotec, Germany) 
and APC-CD133-positive cells were magnetically labelled with Anti-APC 
Multisort Microbeads (Miltenyi, Germany). Then, cells were subjected to 
MACS procedure (see above). After removing the magnetic beads by a 
releasing agent (Anti-APC Multisort Kit, Miltenyi, Germany), any remaining 
magnetically labelled cells were removed by additional MACS procedure. 
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After stopping the release reaction, a PE-labelled vascular endothelial growth 
factor receptor-2 antibody was used (PE-VEGFR-2; R&D Systems, 
Germany) to stain CD133+/VEGFR2+ cells. Finally, cells were incubated with 
anti-PE microbeads (Miltenyi Biotec, Germany) and additional MACS was 
performed.  
 
4.2.4. Determination of progenitor cells  
 
A variety of assays was used to determine the number, differentiation and 
function of EPC. This included the EPC adhesion-related cell culture assay 
for the identification of monocytic EPC, the detection of CD133+/VEGFR-2+ 
cells (human study) or sca1+/flk1+ cells (mouse study), Dil-acLDL uptake, von 
vWF staining, the determination of CFUs, analysis of the migratory capacity 
of monocytic EPC, CD133+-derived EPC, as well as freshly isolated 
CD133+/VEGFR2+ EPC. Incorporation of EPC into endothelial tube like 
structures was additionally measured (see below for details).  
 
4.2.4.1. EPC adhesion-related cell culture assay 
 
2 x 105 PBMCs were cultured on fibronectin-precoated 8-well chamber slides 
(Lab-Tek, Germany) in EBM-2 culture medium supplemented with EGM 
SingleQuots except IGF-1 (Cambrex, Belgium) for 4 days. Appropriate 
amounts of IGF-1 were added. To exclude contamination with mature 
circulating endothelial cells, culture supernatants were removed 8 h after 
initial seeding and non-adherent cells were placed to new fibronectin-
precoated chamber slides. After dilution dil-acLDL (Molecular Probes, 
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Eugene, USA) and FITC-conjugated lectin from Ulex europaeus (UEA-1; 
Sigma, Germany) in serum-free EBM2 media, cells were washed twice and 
incubated for 4 h at 37 °C in EBM2 medium containing 10 µg/ml dil-acLDL 
and 10 µg/ml UEA-1. After washing, cells were observed by fluorescence 
microscopy. Only double positive (dil-acLDL and UEA-1) cells were counted 
in at least 4 independent randomly selected high-power fields. Additionally, 
EPC were co-stained with an anti-vWF antibody (Sigma, Deisenhofen, 
Germany). 
 
4.2.4.2 Detection of CD133+/VEGFR-2+ (human) and sca-1+/flk1+ 
(mouse) cells 
 
PBMCs were isolated by Ficoll® density centrifugation as described 
previously. 2x105 PBMCs were incubated with a vascular endothelial growth 
factor receptor-2 antibody (VEGFR-2; Reliatech, Braunschweig, Germany) 
for 15 min at 6°C and subsequently with a FITC-conjugated mouse IgG 
monoclonal antibody. After washing cells were co-stained with an APC-
coupled monoclonal mouse antihuman CD133 antibody (Miltenyi Biotec, 
Germany). In parallel experiments, appropriate isotype controls were added 
(APC-conjugated mouse IgG2b and FITC-conjugated mouse IgG monoclonal 
IG). At least 20,000 cells were acquired using a FACSCalibur cytometer 
(Becton Dickinson). The number of progenitor cells was expressed as a 
percentage of all PBMCs and in relation to total leukocytes.  
For the detection of mouse EPC, 100 µl of whole blood was stained with a 
FITC-conjugated rat anti-mouse Ly-6A(Sca-1) and a phycoerythrine (PE)-
conjugated rat anti-mouse Flk-1 (VEGF-R2, Ly-73) monoclonal antibody 
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(both BD Pharmingen, Germany), or the respective isotype controls. After an 
incubation period of 45 min at 4°C, erythrocytes were lysed (BD FACS Lysing 
Solution; BD Pharmingen, Germany) and remaining cells subjected to 
standard FACS analysis. 
 
4.2.4.3. Determination of endothelial colony forming units  
 
See 3.2.4.3. for details. 
 
4.2.4.4. Incorporation into endothelial tube like structures 
 
 
Dil-acLDL pre-labelled EPC (2 x 104 cells) were mixed with human umbilical 
vein endothelial cells (HUVECs; 4 x 104) on an 8-well glass slide precoated 
with 100 µL Matrigel (BD Bioscience, Germany) in 200 µL EBM-2 medium 
with supplements (except IGF-1 and FCS, Cambrex, Belgium) with the 
addition of 0 – 100 ng/ml IGF-1 (Sigma-Aldrich, Deisenhofen, Germany) or 
GH (Pharmacia, Erlangen, Germany, 10-100 ng/ml). Further, the 100 ng/ml 
IGF-1 group was pre-treated (30min) with an inhibitory IGF-1 receptor (IGF-
1R) antibody (10 µg/ml) or a phosphoinositide 3 (PI-3)-kinase inhibitor 
(wortmannin, 100 nM, Sigma-Aldrich, Deisenhofen, Germany). After 24 h of 
incubation in 5% CO2 humidified atmosphere at 37 °C, cells were co-stained 
with UEA-1 and examined under a fluorescence microscope. The amount of 
incorporated dil-acLDL labelled EPC in formed endothelial tubes was 
determined. At least four randomly selected high-power fields were examined 
in blinded experiments. At least five experiments were done per study group. 
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4.2.4.5. Cellular migration assay 
 
 
Migratory capacity of monocytic, CD133+ derived or freshly isolated 
CD133+/VEGFR2+ EPC (see 4.2.3. for details of the isolation process) was 
investigated using the modified Boyden chamber assay as described 
previously. In brief, IGF-1 (10-100 ng/ml) or GH (10-100 ng/ml) pre-treated 
(24h) monocytic (1 x 105), CD133+-derived (1 x 104) or CD133+/VEGFR2+ 
EPC (1 x 104)  were cultured in inlets (Falcon HTS Fluoro Blok insert, 8-µm 
pore size), which were placed in 24-well culture dishes containing endothelial 
basal medium (Clonetics, Germany) and 50 ng/mL VEGF, and 100 ng/mL 
SDF-1 to measure the migratory capacity of EPC. After 24h, migrated cells 
on the bottom of the membrane were stained with dil-acLDL and counted by 
fluorescence based microscopic evaluation of the bottom side of the 
membrane. After magnetic affinity cell sorting (MACS; see 4.2.3.), CD133+ 
progenitor cells were cultured for 14 days on fibronectin coated dishes with 
EBM-2 medium, supplements (Cambrex, Belgium) and 20% FCS to promote 
endothelial differentiation as described (66). Additionally, migration assays of 
IGF-1 treated freshly CD133+-derived EPC were performed. Cells not 
migrated through the membrane were not detected by this method. Additional 
migration assays were performed with human mesenchymal stem cells 
(hMSC) obtained from Cambrex (Belgium), that were cultured and expanded 
in mesenchymal stem cell medium (MSCGM with SingleQuots; Cambrex, 
Belgium). hMSC were treated with or without IGF-1 (100ng/ml) for 24h before 
starting the migration assay. 
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4.2.5. Expression of the IGF-1 receptor on EPC 
 
IGF-1 receptor expression was determined in CFU and monocytic EPC. IGF-
1R expression was determined after addition of an anti-IGF-1R antibody 
(R&D Systems, Wiesbaden, Germany) for 12h. Thereafter cells were washed 
and a rhodamine-labelled mouse IgG antibody was added for 4h. In addition, 
cells were stained with FITC-labelled UEA-1 as described above.  
 
4.2.6. Quantification of eNOS and IGF-1 receptor gene expression 
of EPC  
 
Total RNA was isolated from EPC of young, middle-aged (before and after 
GH treatment) and aged individuals according to the manufacture’s 
instructions (Qiagen, Germany). mRNA expression of human eNOS and IGF-
IR were quantified by real-time PCR (iCycler; Bio-Rad Laboratories). PCR 
amplification was performed for 45 cycles using SYBR Green at a primer 
annealing temperature of 60°C. Oligonucleotide sequences were: eNOS-
sense: 5´-CGG CAT CAC CAG GAA GAA GA-3´ and antisense: 5´-CAT 
GAG CGA GGC GGA GAT-3´. IGF-IR- sense: 5´-AAG GCT GTG ACC CTC 
ACC AT-3´ and antisense: 5´-CGA TGC TGA AAG AAC GTC CAA-3´. Gene 
expressions were normalised to glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH): sense primer: 5´-CCA CAT CGC TCA GAC ACC AT-3´ antisense 
primer: 5´-CCA GGC GCC CAA TAC G-3´. In conventional RT-PCR, all 
primers generated only one amplification band visualised by agarose gel 
electrophoresis, demonstrating specificity. For each gene, a standard was 
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constructed by cloning the RT-PCR product into a pCR2.1-TOPO vector 
(Invitrogen). The identity of the insert was confirmed by sequencing (T7 
promoter). Serial 10-fold dilutions of the generated plasmid were used as 
standard curve for quantifications. Results were given as gene of interest 
relative to GAPDH. 
 
4.2.7. Western Blotting analysis 
 
EPC were cultured for 4 days in the presence of endothelial growth media 
(EBM-2 supplemented with EBM SingleQuots (Clonetics, Germany) and 20% 
FCS). Then, medium was switched to FCS- and IGF1-free EBM-2 medium 
and cells were treated with ascending concentrations of IGF-1 or GH for 8h. 
Protein content of cell lysates was determined by Smith assay. Cell lysates 
were mixed with sample loading buffer and separated under reducing 
conditions on 12% SDS-polyacrylamide gel. Proteins were electro-transferred 
onto PVDF membranes (Immun-Blot 0.2 µm, Bio-Rad), incubated for 1 
hour in Tris buffered saline-Tween (TBS-T) with 5% blocking agent 
(Amersham), and followed by overnight incubation at 4°C with primary 
antibodies. The bands were detected using a chemiluminescence assay 
(ECL+Plus, Amersham). Primary antibodies used included anti-eNOS, anti-
phospho-eNOS (Ser 1177) (BD Bioscience, Heidelberg, Germany), anti-Akt, 
anti-phospho-Akt (Cell Signaling Technologies, Beverly, USA) and anti-
GAPDH (Abcam, Cambridge, United Kingdom).  
 
 57
 
4.2.8. Determination of EPC-eNOS activity   
 
See 3.2.5 for details. 
 
4.2.9. Small interference (si)RNA-mediated knockdown of eNOS in 
EPC 
 
EPC cultured for 4 days were transfected with eNOS-siRNA using the 
BLOCK-iT™ Transfection Kit (Invitrogen, Germany). We incubated EPC with 
the siRNA oligonucleotide HSS107238 (150nM) from the NOS3 Stealth™ 
Select RNAi Kit (Invitrogen, Germany) for 48h to downregulate eNOS 
expression. FITC-labelled scrambled siRNA (Control-FITC block-it 
fluorescent Oligo #2013, Invitrogen, Germany) was used as a negative and 
transfection control. eNOS expression was monitored by Western blotting 
(see 4.2.7.). 
 
4.2.10. Acidic beta-galactosidase staining of EPC 
 
After culturing EPC for 4 days and subsequent treatment, cells were fixed 
with a glutaraldehyde/formaldehyde solution and stained with beta-
galactosidase staining solution for 48h as described (105).  In addition the 
total cell number was assessed. The absolute numbers of beta-
galactosidase-positive cells were counted out of 500 cells. 
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4.2.11. Assessment of progenitor telomerase activity 
 
CD34+, CD117+ and CD133+ positive cell fractions were isolated by magnetic 
cell sorting (see 4.2.3.) and found the highest telomerase activity in CD133+ 
cells. Telomerase activity was measured in isolated CD133+ progenitors and 
cultured EPC using a commercially available PCR-based assay according to 
the manufacturer’s protocol. Telomeric repeat amplification protocol (TRAP) 
assays were performed using biotin-labelled TS primers, as described (106). 
 
4.2.12. Mouse in vivo studies 
 
The effects of both GH and IGF-1 treatment in mice were analysed. In 
addition, GH induced changes in EPC levels and function during interruption 
of IGF-1 receptor signalling in vivo by a applying a blocking antibody or a 
small molecule inhibitor were investigated, as detailed below.  
To test whether GH directly or via increase of IGF-1 improves EPC number 
and function, male mice (6-8 months old, Harlan-Winkelmann, Germany) 
were treated intraperitoneally either with placebo (150 µL PBS; n=6), GH 
(Sigma-Aldrich, Germany; 2.5 µg GH/g/day solved in 150 µl PBS once per 
day for 2 or 7 days; each n=6) or mouse IGF-1 (Sigma-Aldrich, Germany; 1.5 
µg mouse IGF-1 / g body weight solved in 150µl PBS for three times per day 
for 2 days; n=5) (see (107; 108) for dose selection). Then, mouse EPC 
number (sca1+/flk1+ cells) was determined by FACS analysis; see 4.2.4.2), 
as well as EPC function (cellular migration assay; see 4.2.4.5).  
In a further in vivo study mice were treated with GH (2.5 µg GH/g/day solved 
in 150µl PBS once per day for 7 days) and the IGF-1 receptor was 
 59
systemically blocked either with a neutralising IGF-1 receptor antibody 
(#MAB391, R&D Systems, Germany; 50 µg/day/animal for 7 days) or a diaryl 
urea compound (N-(2-methoxy-5-chlorophenyl)-N’-(2-methylquinolin-4-yl)-
urea; IGF-1R Inhibitor II, Cat. No. 407248, Calbiochem, Germany; 100 mg/kg 
every second day for 7 days), which recently was described to be a selective 
and highly potent inhibitor of the IGF-1 receptor by blocking 
autophosphorylation (both in human cell lines and in mice in vivo studies; 
(109)). After treatment mouse EPC number (sca1+/flk1+ cells by FACS 
analysis; see 4.2.4.2), as well as EPC function was determined (cellular 
migration assay; see 4.2.4.5).  
 
4.2.13. Statistical analysis 
 
See 3.2.6. 
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4.3. Results 
 
4.3.1. Age-related decline in IGF-1 levels, EPC number and 
function  
 
IGF-1 plasma levels were significantly reduced in the elderly and middle-
aged as compared to young men (120.8±10.5 ng/ml and 126.0±7.2 ng/ml vs 
223.1±15.7 ng/ml; p<0.0001). Older individuals had significantly lower 
concentrations of circulating CD133+/VEGFR2+ cells (4.4.1. (Figure 1A)). 
EPC function was impaired with age, as determined by reduced colony 
forming capacity (4.4.1.  (Figure 1B)), and impaired cellular migratory 
capacity (4.4.1. (Figure 1C)). Gene expression of eNOS was significantly 
reduced in EPC from aged subjects, whereas expression of the IGF-1R was 
unchanged (4.4.1. (Figure 1D)). 
 
4.3.2. Treatment with recombinant human growth hormone (GH) of 
middle-aged individuals restored IGF-1 levels, increased EPC 
number and improved EPC function 
 
A ten day treatment of middle-aged men with GH increased IGF-1 serum 
levels from 126.0±7.2 ng/ml to 241.1±13.8 ng/ml (p<0.0001). 
CD133+/VEGFR2+ cells were 2-fold increased after GH treatment (4.4.1. 
(Figure 1A)). Likewise, the number of endothelial CFU was increased in 
treated individuals (4.4.1. (Figure 1B)) and both CD133+/VEGFR2+ cells and 
CFUs correlated with IGF-1 plasma levels (r=0.46, p<0.01 and r=0.60, 
p<0.0001). Haemoglobin (14.65±0.62 g/dl vs 14.46±0.73 g/dl), total 
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erythrocyte (4.83±0.09x106/µl vs 4.75±0.12x106/µl) or leukocyte numbers 
(5.01±1.00x103/µl vs 5.02±0.99x103/µl) were unchanged by GH treatment. 
Migratory capacity of EPC was improved after GH treatment (4.4.1. (Figure 
1C)). eNOS expression in isolated EPC was significantly increased by 64% 
after 10 day GH treatment, whereas that of the IGF-1R was basically 
unchanged (4.4.1. (Figure 1D)). 
 
4.3.3. IGF-1 mediates the effects of GH treatment on EPC number 
and function in aged mice 
 
Both treatment of male mice with GH (7 days) or IGF-1 (2 days) increased 
systemic IGF-1 levels [control PBS-treated mice: 230±38 ng/ml; GH (7d): 
520±207 ng/ml (p<0.001); IGF-1 (2d): 631±142 ng/ml (p<0.0001)] as well as 
sca1+/flk1+ EPC in peripheral blood and improved EPC function (see 4.4.1.  
(Figure 1E,F)). In contrast, a 2 day treatment with GH did not significantly 
increase IGF-1 levels (GH, 2d: 243±6 ng/ml) nor EPC number or function 
indicating IGF-1 to be the main mediator of the observed effects of GH on 
EPC. Regression analysis revealed a positive correlation between IGF-1 
levels and EPC number (r=0.45; p<0.05) or EPC migratory capacity (r=0.49; 
p<0.05). When the IGF-1 receptor was blocked either by a neutralising 
antibody or a specific IGF-1 receptor inhibitor (see 4.1.12.), the GH-mediated 
effects on circulating EPC numbers (4.4.1. (Figure 1G)) and function (4.4.1. 
(Figure 1H)) were abolished.  
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4.3.4. IGF-1 improves differentiation and function of EPC from 
young and elderly individuals via the IGF-1 receptor 
 
To test whether increased IGF-1 concentrations may mediate the observed 
effects of GH treatment, presence of the IGF-1R on EPC was investigated.  
Indeed, IGF-1R was expressed on various subtypes of progenitor cells, e.g. 
early outgrowth EPC (CFU assay) and adherent dil-acLDL+/UEA-1+ EPC, 
which have previously shown to be of monocytic origin (71), but bind 
endothelial lectins and express endothelial proteins, such as the vWF (4.4.2. 
(Figure 2), 4.4.3.  (Figure 3)). To test whether the IGF-1R is functionally 
active further in vitro studies were performed. IGF-1 treatment enhanced 
formation of endothelial CFU and increased development of UEA-1+/dil-
acLDL+ cells from cultured PBMC, indicating stimulation of EPC 
differentiation and function (4.4.4. (Figure 4A, B)). Migratory capacity of 
monocytic EPC was likewise improved by IGF-1 treatment (4.4.4. (Figure 4A, 
B)). In addition, IGF-1 stimulated migration of CD133+ derived and freshly 
isolated CD133+/VEGFR2+ EPC, whereas GH was without effect (4.4.5. 
(Figure 5A,C)). The ability to incorporate into forming vascular networks on 
matrigel was significantly increased in IGF-1 pre-treated EPC (4.4.4. (Figure 
4A, B)). In contrast, GH treatment in vitro, with the exception of minor 
improvement of cellular migration, did not display significant effects on EPC 
in the aforementioned assays (4.4.4. (Figure 4)). Inhibition of the IGF-1R by 
pre-treatment with an inhibitory IGF-1R antibody abolished the effects of IGF-
1 (4.4.4. (Figure 4)). IGF-1 treatment improved migratory capacity of EPC 
from elderly individuals, as compared with untreated cells (4.4.5. (Figure 
5B)).   
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To test whether the migratory potential of IGF-1 may apply to other kinds of 
stem cells we tested the effects of IGF-1 on human mesenchymal stem cells 
(hMSC). In contrast to the effects on EPC, IGF-1 (100 ng/ml) did not improve 
the migratory capacity of hMSC (89.5±10.7 vs 78.5±3.2 migrated 
hMSC/microscopic field; n=8; p=n.s.). 
 
4.3.5. IGF-1 increases phosphoinositide 3-kinase/Akt-mediated 
expression and phosphorylation of eNOS in cultured EPC  
 
As EPC function and differentiation is in part regulated via eNOS (44), GH or 
IGF-1 treatment was tested for impact on PI-3-kinase/Akt/eNOS signalling. 
Treatment of EPC with IGF-1 induced Akt phosphorylation, as well as 
expression and phosphorylation (Ser1177) of eNOS (4.4.6. (Figure 6A)). 
Functionally, IGF-1 treatment increased eNOS activity (4.4.6. (Figure 6B)). 
Inhibition of the PI3-kinase prevented IGF-1 mediated Akt phosphorylation, 
as well as eNOS expression and phosphorylation. Blocking of the PI3-kinase 
pathway reduced EPC differentiation and function (4.4.4. (Figure 4A, B)). 
Inhibition of the IGF-1R with an inhibitory antibody completely abolished IGF-
1 induced phospho-Akt/eNOS signalling (4.4.6. (Figure 6A)) and eNOS 
activity (4.4.6. (Figure 6B)). In contrast, GH had minor effects on eNOS 
expression, but did not affect Akt or eNOS phosphorylation or eNOS activity 
(4.4.6. (Figure 6)). Functional knockdown of eNOS by small interference RNA 
abolished the stimulatory IGF-1 effect on cellular migration of EPC, whereas 
addition of transfection media or scrambled siRNA had no significant effects 
(4.4.7. (Figure 7)).  
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4.3.6. IGF-1 impacts EPC cellular senescence and telomerase 
activity 
 
Vascular endothelial cells with senescence-associated phenotypes are 
present in human atherosclerotic lesions of elderly patients (110). Acidic 
beta-galactosidase can be detected in cultured EPC as a biochemical marker 
for the onset of cellular senescence (105; 111).  Cultured EPC from healthy 
individuals treated with IGF-1 displayed significantly fewer beta-
galactosidase positive cells than cells without the addition of IGF-1 (6.5±3.3 
vs. 21.5±5.3 beta-galactosidase positive cells; p<0.001) and showed 
enhanced telomerase activity, that was attenuated by PI3-kinase inhibition or 
blocking of the IGF-1R (4.4.8. (Figure 8A)). Growth hormone was without 
effect on telomerase activity. 
 
Elderly individuals displayed significantly increased number of beta-
galactosidase positive EPC compared to EPC isolated from young subjects, 
demonstrating increased cellular senescence (4.4.8. (Figure 8B)), whereas 
telomerase activity in isolated progenitor cells was reduced (4.4.8. (Figure 
8C)). Treating cultured EPC from aged individuals with IGF-1 reduced 
cellular senescence (4.4.8. (Figure 8B)). Likewise, growth hormone mediated 
IGF-1 increase in middle-aged subjects resulted in reduced EPC senescence 
(4.4.8. (Figure 8D,E)). Telomerase activity of CD133+-enriched progenitor 
cells was 2.3-fold (p<0.05) increased after treatment with GH and was 
comparable to that of young individuals (4.4.8. Figure 8C)).  
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4.4. Figures 
4.4.1. Figure 1 
 
 
 
 
Circulating EPC number and function of middle-aged subjects before and after 
treatment with recombinant growth hormone compared to young controls and 
elderly individuals, as well as in aged mice.  
Clinical study (A-D): A) Number of circulating CD133+/VEGFR2+ cells in % of 
mononuclear cells and B) number of endothelial colony forming units in young 
(n=10), middle-aged before and after treatment with recombinant human growth 
hormone (GH; each n=16) and elderly subjects (n=12). C) Migratory capacity of 
EPC from the various study groups. D) Gene expression of IGF-1R and eNOS 
relative to GAPDH in EPC derived from the various study groups. MA=middle-aged. 
Results represent mean ± SEM. 
Mouse study (E-H): E) Number of circulating sca1+/flk1+ cells in % of mononuclear 
cells and (F) migratory capacity of monocytic EPC of mice treated with placebo 
(control), IGF-1 (2 days), GH (2 or 7 days). G) Number of circulating sca1+/flk1+ cells 
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in % of mononuclear cells and (H) migratory capacity of monocytic EPC of mice 
treated with placebo (control), GH (7 days), GH (7 days) + inhibitory IGF-1 receptor 
antibody (#MAB391, R&D Systems) or GH (7 days) + IGF-1 receptor inhibitor II 
(Calbiochem, Germany). n=4-6 per study group. Results represent mean ± SEM. 
 
 
 
 
 
4.4.2. Figure 2 
 
 
 
Expression of the insulin-like growth factor-1 receptor on human endothelial 
progenitor cells. 
Binding of the FITC-conjugated lectin UEA-1 to the surface of monocytic endothelial 
progenitor cells received by the adhesion related selection method (A,B) and to 
endothelial colony forming units (G,K) is shown as a positive control. Figures B and 
H demonstrate expression of the IGF-1 receptor on monocytic EPC and colony 
forming units, respectively. Figures E and L show findings when only the second 
rhodamine-labeled IgG antibody was used (negative control). Figures C, F, I and M 
show the merged pictures. Representative pictures of a minimum of five 
experiments are shown. 
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4.4.3. Figure 3 
 
 
 
 
Expression of the von Willebrand factor on human endothelial progenitor 
cells. 
Expression of the vWF in EPC including formation of typical Weibel-Palade bodies 
(intense green spots) (A). Figures B show findings with the second IgG antibody 
alone (negative control). Dil-acLDL uptake (C,D) and nuclear staining by DAPI (E,F). 
Merged pictures (G,H). Representative pictures of a minimum of three experiments 
are shown. 
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4.4.4. Figure 4A 
 
 
  
Figure 4B 
Effects of IGF-1 and recombinant 
human growth hormone on 
endothelial progenitor cell function. 
Colony forming capacity (CFU), 
differentiation of dil-acLDL+/UEA-1+ 
cells from peripheral blood 
mononuclear cells (dil-acLDL/UEA-1), 
migratory capacity (migration) and 
incorporation of EPC into vascular 
structures on matrigel (incorporation) is 
shown in EPC after 24h of treatment 
with GH (100ng/ml), IGF-1 (100ng/ml), 
and the concomitant treatment of IGF-1 
with the PI3-kinase inhibitor wortmannin 
(100nM) or an inhibitory IGF-1 receptor 
antibody (10 µg/ml). Representative 
pictures (A) and the statistical summary 
(B) of a minimum of five experiments 
per study group are shown. *=p<0.05 
vs control; ***=p<0.0001 vs control; 
†=p<0.05 vs IGF-1 100ng/ml; 
††=p<0.01 vs IGF-1 100ng/ml; 
†††=p<0.0001 vs IGF-1 100ng/ml. 
Results represent mean ± SEM. 
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4.4.5. Figure 5 
 
 
 
Migratory capacity of CD133+-derived EPC, freshly isolated CD133+/VEGFR2+    
EPC and rescue of impaired function of EPC derived from elderly subjects by 
IGF-1. 
A) CD133+ cells were isolated by MACS and cultured for 14d with EBM-2 (with 
supplements and 20% FCS) to induce an endothelial phenotype. Prior to the 
migration assay cells were treated for 24h with IGF-1 (100ng/ml), IGF-1 and the PI3-
kinase inhibitor wortmannin (100nM), IGF-1 or an inhibitory IGF-1 receptor antibody 
(10 µg/ml) or GH (100ng/ml) (n=5). B) Migratory capacity of monocytic EPC derived 
from elderly subjects before (left) and after (right) ex vivo treatment with IGF-1 
(100ng/ml for 24h). C) Migratory capacity of freshly isolated CD133+/VEGFR2+  EPC 
after treatment for 24h with IGF-1 (100ng/ml), IGF-1 and the PI3-kinase inhibitor 
wortmannin (100nM), IGF-1 or an inhibitory IGF-1 receptor antibody (10 µg/ml) or 
GH (100ng/ml) (n=5). Results represent mean ± SEM. 
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 4.4.6. Figure 6 
 
 
 
Expression, phosphorylation and function of eNOS in human EPC. 
A) Protein expression of phosphorylated Akt, eNOS, phosphorylated eNOS and 
GAPDH in cultured EPC with treated with growth hormone (GH; 100ng/ml) or IGF-1 
(100ng/ml) with or without PI3-kinase inhibition (wortmannin, 100nM) or addition of 
an inhibitory IGF-1 receptor antibody (10µg/ml). B) NOS activity as determined by 
measuring the conversion of L-[guanidino-15N2]arginine to 15N-nitrite in cultures of 
human EPC. 14N-nitrite was used as internal standard. At least four experiments 
were performed per study group. Results represent mean ± SEM. 
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4.4.7. Figure 7 
 
 
 
siRNA mediated knockdown of eNOS in human EPC blocks stimulatory IGF-1 
effects on migratory capacity. 
A) Detection of transfected EPC with FITC-labeled scrambled siRNA. B) Western 
blotting of eNOS and GAPDH in EPC 48h after transfection with eNOS siRNA 
(150nM). C) Migratory capacity in controls and IGF-1 treated EPC. The IGF-1 group 
was concomitantly treated with transfection media (TM), scrambled siRNA (150nM) 
or eNOS siRNA (150nM). At least four experiments were performed per study 
group. Results represent mean ± SEM. 
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4.4.8. Figure 8 
 
 
Telomerase activity and cellular senescence of EPC in response to IGF-1. 
A) Telomerase activities in cultured monocytic EPC after treatment with IGF-1 
(100ng/ml), IGF-1 and the PI3-kinase inhibitor wortmannin (100nM), IGF-1 and an 
inhibitory IGF-1 receptor antibody (10µg/ml) or GH (100ng/ml). At least five 
experiments were performed per study group. B) Detection of beta-galactosidase 
positive EPC derived from young or elderly subjects before and after ex vivo 
treatment with IGF-1 (100ng/ml for 24h). C) Telomerase activities in CD133+ 
progenitors isolated from young, middle-aged (before and after GH treatment for 
10d) and elderly subjects. D) Detection of beta-galactosidase positive EPC derived 
from middle-aged subjects before and after a 10d treatment with GH. Results 
represent mean ± SEM. 
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4.5. Discussion 
 
The results of this part of the thesis demonstrate that the age-related decline 
in EPC number and function can be restored by growth hormone mediated 
increase of IGF-1 levels. In vitro and in vivo studies extend and support these 
clinical observations. IGF-1, but not GH enhanced EPC differentiation and 
function involving PI3-kinase/phosphorylated Akt-mediated increase in eNOS 
phosphorylation and activity. 
 
The finding of reduced amounts of circulating EPC with increasing age is in 
line with age-dependent reduction of EPC number in patients with coronary 
artery disease independent of risk factors for atherosclerosis or of cardiac 
function (30). Functional impairment of EPC from elderly subjects is related 
to endothelial dysfunction (31). An important study has shown, that bone 
marrow transplantation from young, but not old, non-atherosclerotic mice 
prevented atherosclerosis progression in apolipoprotein E knockout 
recipients, suggesting that deficient vascular repair due to increased age is a 
critical determinant of disease initiation and progression (112). Taken 
together the data suggest that the age-related decline in progenitor number 
and function may indeed contribute to the progression of atherosclerosis. In 
line with our findings, recent independent studies have shown that patients 
with reduced circulating progenitor cells are at increased risk for 
cardiovascular events and death independent of other cardiovascular risk 
factors (14; 15).  
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As EPC mobilisation and revascularisation is in part regulated by NO (17; 21; 
22; 113; 114), growth hormone-deficient patients with impaired systemic NO 
formation are expected to be at increased risk for cardiovascular disease 
(115; 116). Treatment of these patients with recombinant human growth 
hormone (GH) results in an IGF-1-related stimulation of endothelial NO 
formation, decreased peripheral arterial resistance, and reversal of 
morphological and functional atherosclerotic changes in major arteries (104; 
115). IGF-1 is synthesised by large in the liver in response to GH (117). Low 
circulating IGF-1 levels are independently associated with increased risk for 
coronary artery disease or fatal ischemic heart disease (33; 118-120).  In 
contrast, increased IGF-1 levels are related to reduced mortality in elderly 
individuals (120). Thus, restoration of IGF-1 appears to provide protection 
from cardiovascular disease progression (103; 121). However, this remains 
to be shown in future trials. 
 
The presented data provide a potential mechanistic link between IGF-1 and 
cardiovascular disease. The age-dependent reduction in IGF-1 levels and 
circulating EPC numbers, as well as impaired EPC function points to a causal 
relationship. Indeed, ten days of GH treatment increased IGF-1 levels and 
circulating EPC in middle-aged subjects to the values observed in the 
younger group. As impaired function of EPC from older patients with 
ischemic heart disease may limit their therapeutic potential for clinical cell 
therapy (13; 122), reversal of functional impairment of EPC in older 
individuals by GH treatment has important clinical implications.  The 
opportunity exists to improve function of impaired EPC so as to optimise cell 
transplantation protocols. 
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Further evidence for a direct relationship between IGF-1 and EPC comes 
from the present in vivo and in vitro studies. Treatment of mice with IGF-1 
improved number and function of EPC similar to a 7 day treatment with GH 
that significantly increases systemic IGF-1 levels, whereas a short term GH 
treatment did not increase IGF-1 nor EPC levels. Additionally, interruption of 
IGF-1 / IGF-1R signalling completely prevented the GH-mediated increase in 
EPC number and function.  
 
Likewise, IGF-1, but not GH enhanced EPC differentiation, increased colony 
forming and migratory capacity, and stimulated EPC incorporation into tube-
like structures. In addition, telomerase activity in EPC was increased and 
cellular senescence attenuated. The finding that a 24h treatment period of 
cultured EPC with IGF-1 reduces the amount of senescent cells is intriguing 
but needs further discussion. It is possible that IGF-1 indeed is capable to 
reduce senescence in cultured EPC very rapidly (based on the reduced 
amount of beta-gal positive cells per microscopic field). However, as we did 
not measure alterations of cell number, it also could be that IGF-1 had a 
positive effect on EPC proliferation within this short timeframe. Then it may 
be possible that the amount of non-senescent cells increased within 24h, 
whereas the number of senescent cells did not. The result would be a 
“reduction” in the number of beta-gal positive cells relative to the total number 
of cells per microscopic field. Future studies should take this into account.  
Of importance, impaired function of EPC from aged subjects was normalised 
by IGF-1. In vivo, IGF-1 directly opposed endothelial dysfunction by 
enhancing NO production (reviewed in (123)). IGF-1 increases NOS activity 
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by interacting with a tyrosine kinase membrane receptor that activates 
phosphoinositide 3-kinase (124), which in turn activates the serine/threonine 
kinase Akt signalling pathway (125). In the heart, IGF-1 mediated activation 
of this pathway promoted cell growth and survival (126). In the present study, 
stimulation of PI3-kinase-dependent Akt phosphorylation and eNOS activity 
by IGF-1 was shown in human EPC. Functional knockdown of eNOS using 
siRNA abolished the IGF-1 effects, underlining the pivotal role of eNOS in the 
stimulatory effects of IGF-1 on human EPC. This also explains at least in part 
the detrimental effects of the endogenous NOS inhibitor ADMA on EPC 
function, as shown above (see Chapter III;  3.2.to 3.4.). In contrast, GH 
treatment may also alter levels of glucose (Chapter V) or ADMA (Chapter 
III). Experiments to clarify this hypothesis and a detailed discussion about the 
potential relationships between GH, ADMA and glucose will be given in 
Chapter VI. 
 
Within the heart, the IGF-1/IGF-1R system induces division of cardiac stem 
cells, up regulates telomerase activity thereby counteracting replicative 
senescence and preserves the pool of functionally active cardiac stem cells 
(34; 35; 127). Myocardial regeneration may in part be mediated by IGF-1, 
and results in delayed onset of heart failure (128). IGF-1 promotes 
engraftment, differentiation, and functional improvement after transfer of 
embryonic stem cells for myocardial restoration (129). Urbanek and co-
workers found that resident cardiac stem cells express the IGF-1R (34), and 
the present data demonstrate expression of a functionally active IGF-1R in 
EPC. Besides cardiovascular progenitor cells, IGF-1R expression has been 
observed in erythroid (130), osteogenic (131), and neural (132) progenitor 
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cells. Existence of an IGF-1R may be a general feature of progenitor cells. 
Targeting the IGF-1R on EPC opens a new line of therapeutic possibilities 
such as the use of GH or IGF-1 to restore progenitor cell function (11). In 
contrast, in human mesenchymal stem cells (hMSC) IGF-1 appears to 
function as a differentiation factor. In line with this finding we found no 
stimulatory role of IGF-1 on migratory capacity of cultured hMSC. 
 
Transgenic IGF-1 over expression led to increased telomerase activity and 
preservation of functional capacity of aging cardiac stem cells (35). This is of 
importance as chronic oxidative stress and endogenous NO synthase 
inhibitors compromise telomere integrity, accelerate the onset of senescence 
in human endothelial cells and finally are associated with reduced EPC 
numbers (100; 133). Recent findings suggest that vascular cell senescence 
induced by telomere shortening may contribute to atherogenesis (110). 
Importantly, Brouilette and colleagues recently demonstrated prediction of 
future cardiovascular events in middle-aged men to be possible by 
measurements of mean leukocyte telomere length (134). Age-related 
diseases are characterised by short telomeres, which can compromise cell 
viability. Loss of functional telomere length below a critical threshold activates 
programs leading to cell senescence or death. Telomerases elongate 
telomeres especially in stem and progenitor cells (135). Telomere shortening 
in progenitor cells could limit their functions including repair capacity of the 
vessel wall (136). Telomerase activity is regulated by NO and decelerates 
telomere degradation in adult vascular progenitor cells (137), whereas the 
endogenous NOS inhibitor ADMA impairs telomerase activity (138). In this 
part of the thesis telomerase activity in CD133+ purified progenitor cells from 
 78
middle-aged individuals before and after treatment with recombinant human 
growth hormone was analysed. Telomerase activity decreased with age, but 
growth hormone treatment enhanced both systemic NO bioavailability and 
telomerase activity in progenitor cells from middle-aged men to levels 
comparable to young controls. Interestingly, a positive correlation was found 
between telomerase activity in isolated progenitor cells and urinary cyclic 
guanosine monophosphate (cGMP) levels (r=0.79; p=0.001), the latter being 
a good marker for overall NO bioavailability in the body. This underlines the 
hypothesis that NO per se may regulate telomere biology in progenitor cells 
including EPC. The observation of reduced leukocyte telomere length in 
middle-aged men with severe coronary artery disease (134) could thus reflect 
reduction in systemic NO bioavailability. Gradual decrease in NO 
bioavailability with age and/or during cardiovascular disease likely reduces 
telomerase activity especially in circulating vascular progenitor cells thus 
limiting the endogenous repair capacity for damaged vascular walls. 
Targeting endothelial progenitor telomere biology may therefore be a 
promising tool to combat age-related syndromes including atherosclerosis. 
The finding that augmented IGF-1 levels increase telomerase activity and 
prevent cellular senescence of aged and dysfunctional progenitor cells may 
have important clinical implications especially in diseases with increased 
cellular senescence, such as atherosclerosis. As supplementation with 
growth hormone increases systemic NO bioavailability and subsequent rise 
in EPC number and function via the IGF-1 receptor (139), this might be an 
interesting therapeutic option in atherosclerotic diseases with impaired EPC 
function, although this needs to be tested in larger and controlled study 
cohorts. It should be pointed out that effects of GH administration on patients 
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with heart failure have been inconsistent. In some studies, GH greatly 
benefited patients with idiopathic or postischemic dilated cardiomyopathy, 
whereas in others it exerted little or no effect (140-142). Indeed, as 
suggested by a recent subgroup analysis from the available clinical trials, this 
discrepancy could well be explained by the heterogeneity in the circulating 
IGF-I increase in response to the different GH treatment regimens tested in 
CHF patients (143). A recent study indeed shows that a 3 months treatment 
with GH improved exercise capacity and cardiopulmonary performance in 
patients with chronic heart failure (144).  It also may be possible that 
treatment of patients directly with IGF-1 formulations would have better 
effects on prevention and progression of coronary artery disease and/or heart 
failure.  
 
The current study identifies IGF-1 as an important regulator of EPC. 
Correction of age-related decline in number and function of EPC by growth 
hormone-mediated increase in IGF-1 may favour endothelial regeneration at 
sites of tissue damage and finally reduce cardiovascular events. Further 
prospective studies are needed that determine the effects of growth hormone 
mediated IGF-1 increase as a novel therapeutic strategy against vascular 
disorders with impaired number and function of EPC. Such studies are 
currently planned by various groups in Europe and USA. 
 
 
4.6. Limitations 
 
Although the GH/IGF-I axis is involved in maintenance of normal function and 
homeostasis of diverse body functions, it also contributes to the progression 
 80
of a number of common cancers (reviewed in (145)). Although there is no 
evidence of increased incidence of cancer in GH-deficient- or middle-aged 
heart failure patients during GH therapy (146; 147), future clinical trials 
investigating the role of GH or IGF-1 on stem cell biology should be 
performed with caution. 
 
Data on this part of the thesis have recently been published ((62)). 
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Chapter V EPC in diabetes – role of eNOS  
    uncoupling  
 
5.1. Background of the study 
 
Cardiovascular disease is a common complication of diabetes (36; 37). 
Endothelial dysfunction in the pathogenesis of diabetes promotes 
arteriosclerosis (38). Mechanistically, uncoupling of eNOS in blood vessels of 
diabetic patients leads to excessive superoxide anion (O2-) production and 
diminishes NO availability (42; 43; 148). The underlying molecular events are 
not completely clear, but reduction of the essential eNOS cofactor (6R)-
5,6,7,8-tetrahydro-L-biopterin (BH4) and involvement of the protein kinase C 
(PKC) in exaggerated O2- production have been proposed (42; 148). 
 
As discussed in Chapter I decreased levels of circulating EPC are correlated 
with increased risk for coronary artery disease and myocardial infarction (9; 
14; 15; 100). Reduced levels of EPC have been described in both type I and 
type II diabetic patients (10; 39). EPC recruitment for reendothelialisation 
after vascular injury is impaired in diabetes (40; 60). These alterations are 
likely to be involved in the pathogenesis of vascular disease in diabetes (41). 
Although eNOS is of paramount importance for the regulation of mobilisation 
and function of EPC (21; 22), data about the role of eNOS uncoupling in 
diabetic EPC are not available. 
 
EPC are embedded in a microenvironment of bone marrow stromal and 
endothelial cells, and can be translocated to the circulation. NO-mediated 
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signalling pathways have been previously proposed to be essential for EPC 
mobilisation (17; 21; 149). Whether these pathways are altered in diabetic 
bone marrow is not known.  
 
In this part of the thesis the hypothesis was tested if eNOS uncoupling occurs 
in EPC from diabetic patients and if it is involved in impairment of cellular 
function. A potential underlying and mechanistic role of BH4 and protein 
kinase C signaling in glucose-mediated eNOS uncoupling in EPC was further 
analysed. Finally, investigations were performed to study whether low 
circulating EPC levels observed in diabetes may result from alterations in 
bone marrow EPC mobilising pathways and approaches to treatment  were 
developed in vitro.  
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5.2. Methods  
 
5.2.1. Clinical and animal studies 
 
The study conforms to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). The clinical study was approved by the ethical committee of 
the University of Würzburg and informed written consent was obtained from 
patients. 
 
5.2.2. Isolation of bone marrow and peripheral blood mononuclear 
cells (PBMCs)  
 
PBMCs were derived from leucopheresis material of healthy volunteers or 
from total blood of type II diabetic (n=5; age 70.6±1.7 years) and non-diabetic 
patients (n=5; age 70.0±2.9 years), as described (100). Glucose 
concentrations and HbA1c values were determined in the morning after an 
overnight fasting period. Detailed patient characteristics are shown in Table 
1. As diabetes had not been diagnosed previously in these patients, they 
were not on insulin or any oral antidiabetic medication at the time of blood 
withdrawal. Rat PBMCs were isolated by Ficoll density centrifugation (17). 
Hollow bones of rat legs were prepared by standard surgical procedures and 
whole bone marrow was harvested by flushing marrow with 500µl PBS using 
a syringe with a 20-gauge needle as described (17). Bone marrow was 
pelleted and shock-frozen prior to further analysis.  
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5.2.3. Determination of EPC numbers and cellular characterisation  
 
An adhesion-related selection method for isolation of monocytic EPC was 
used, as described (40; 71; 100). PBMCs (2 x 105) were cultured on 
fibronectin-precoated 8-well chamber slides (Lab-Tek, Germany) in EBM-2 
culture medium supplemented with EBM SingleQuots (Clonetics, Germany) 
and 20% FCS for 3 days. To exclude contamination with mature circulating 
endothelial cells, we carefully removed culture supernatant 2h after initial 
seeding and placed it on new fibronectin-precoated chamber slides. EPC 
were characterised by cellular uptake of acetylated LDL (dil-acLDL; 
Molecular Probes, Eugene, USA), binding of FITC-conjugated lectin from 
Ulex europeus (UEA-1; Sigma, Germany), expression of VEGFR-2 and 
eNOS, capacity for integration during endothelial tube formation, cellular 
migration and colony forming unit capacity, as described (17). Additionally, 
EPC were stained with an anti-vWF antibody (Sigma, Deisenhofen, 
Germany). 
 
5.2.4. Animal study protocol  
 
Diabetes was induced by a single intravenous injection of streptozotocin (50 
mg/kg) in male Wistars rats (180–200 g) obtained from Harlan-Winkelmann 
(Borchen, Germany). After 12 weeks hyperglycemia was confirmed by blood 
glucose monitoring system in the morning after an overnight fasting period 
(Ascensia EliteTM, Bayer, Germany). Only streptozotocin–treated rats with 
blood glucose levels >300 mg/dl were included in the study. 
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5.2.5. Western Blot analyses and ELISA  
 
Western Blotting was performed as described (150). Cell extracts were mixed 
with sample loading buffer and separated under reducing conditions on 12% 
SDS-polyacrylamide gel. Proteins were electro-transferred onto PVDF 
membranes (Immun-Blot 0.2 µm, Bio-Rad), incubated for 2 hours in Tris 
buffered saline-Tween (TBS-T) with 5% blocking agent (Amersham), followed 
by overnight incubation at 4°C with primary antibodies. The bands were 
detected using a chemiluminescence assay (ECL+Plus, Amersham). Primary 
antibodies used included mouse anti-eNOS and anti-phospho-eNOS 
(Transduction Laboratories, BD Biosciences, Germany) and mouse anti-
GAPDH (Abcam, Acris, Germany).  
 
5.2.6. Low temperature SDS-PAGE 
 
Cell extracts were mixed with 3X SDS sample buffer (187.5 mM Tris-HCl (pH 
6.8), 6% (w/v) SDS, 30% glycerol and 0.03% (w/v) bromophenol blue and 
15% (v/v) 2-mercaptoethanol) at 0 °C. Samples were loaded on 7.5% 
polyacrylamide gels and subjected to electrophoresis. Gels and buffers were 
cooled to 4 °C prior to electrophoresis and the buffer tank placed in a ice-
bath during electrophoresis. eNOS dimer/monomer protein was detected by 
Western Blot analysis (see 5.2.5.). 
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5.2.7. Detection of reactive oxygen species in total bone marrow 
and EPC 
 
A variety of different techniques were used to measure ROS production, as 
described below: 
 
5.2.7.1. Detection of malondialdehyde (MDA) in bone marrow 
 
 
Malondialdehyde–thiobarbituric acid (MDA-TBA) adducts were measured by 
high-performance liquid chromatography (HPLC) as described (151). Bone 
marrow supernatants were separated and fractionation of the protein-free 
extract was performed using a C18 column (Micro Bondapak, Waters) in an 
HPLC system (Pharmacia LKB; Germany). A flow rate of 1ml/min was used 
at a pressure of 1800psi at 35°C. Exact quantification was achieved using 
1,13,3-tetraethoxypropane standards. 
 
5.2.7.2. Determination of superoxide anions by lucigenin-
enhanced chemiluminescence  
 
Superoxide anion formation was measured by lucigenin-enhanced 
chemiluminescence. Cell extracts were transferred into scintillation vials 
containing lucigenin and Krebs/HEPES buffer (final composition mmol/L: 
lucigenin 0.005, NaCl 99.01, KCl 4.69, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.03, 
NaHCO3 25, Na-HEPES 20, glucose 5.6; pH 7.4). Signals were assessed 
over 20 minutes in a luminometer (Wallac, Freiburg, Germany) at 30s 
intervals. To address the effects of NOS inhibition on superoxide production, 
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aliquots of bone marrow extracts were incubated with NG-nitro-L-arginine (L-
NNA, 1mM) for 20 min.  
 
5.2.7.3. Dihydroethidium assay  
 
The redox-sensitive, cell-permeable fluorophore dihydroethidium (DHE) 
becomes oxidised in the presence of O2− to yield fluorescent ethidium. Thus, 
dye oxidation is an indirect measure of the presence of reactive oxygen 
intermediates. Cultured EPC were incubated with DHE (2.5µM) for 30min. 
After washing mean channel fluorescence of each sample was measured 
during fluorescence-microscopic evaluation of at least 4 different visual fields. 
Intracellular ROS in human EPC were additionally detected using a 
FACSCalibur flow cytometer (Becton Dickinson, San Juan, CA, USA). 
Fluorescence was measured using filter FL-3 (670 nm) and histograms of 
10000 events were analysed per experiment. Degree of fluorescence in EPC 
was then evaluated by using the Cell Quest software (Becton Dickinson). 
 
5.2.8. Detection of reactive nitrogen species (RNS) in EPC 
 
5.2.8.1. 3-Nitrotyrosine assay  
 
Peroxynitrite reacts quickly with a variety of different biomolecules to produce 
3-nitrotyrosine, which therefore is a good biomarker for reactive nitrogen 
species (152). Human EPC were treated with glucose (30mM, 24h) and then 
cell lysates were prepared on ice using cell lysis buffer (Tris-HCl pH7.6,1M;  
EDTA,0.5M; dithiothreitol, 1.25M). 3-nitrotyrosine from cell lysates was then 
isolated by HPLC and subjected to a sensitive gas-chromatography-tandem 
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mass spectrometry method (GC-tandem MS), as recently described (152). 
GC-tandem MS analysis of 3-nitrotyrosine was performed in the electron 
capture negative-ion chemical ionisation mode on a triple-stage quadrupole 
mass spectrometer model ThermoQuest TSQ 7000 (Finnigan MAT, San 
Jose, CA, USA) directly interfaced with a Trace 2000 series gas 
chromatograph equipped with an auto sampler AS 2000 (CE Instruments, 
Austin, TX, USA) (24). These studies were performed together (Dr. Tsikas) 
with the department of Clinical Pharmacology in Hannover, Germany. 
 
5.2.9. Measurements of biopterin content in EPC  
 
 
Measurements of biopterin content in EPCs were performed using HPLC 
analysis and a differential oxidation method as described previously (153). 
The amount of BH4 was determined from the difference between total (BH4 
plus BH2 plus biopterin) and alkaline-stable oxidised (BH2 plus biopterin) 
biopterin. A Nucleosil C-18 column (4,6 x 250 mm, 5 µm) was used with 5% 
methanol/95% water as a solvent at a flow rate of 1.0 ml per minute. The 
fluorescence detector was set at 350 nm for excitation and 450 nm for 
emission. These studies have been performed together with Dr. Widder 
(Emory Hospital, Atlanta, USA).  
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5.2.10. Functional analysis of endothelial progenitor cells 
 
5.2.10.1. Colony forming unit  assay  
 
 
Endothelial CFUs from isolated PBMCs of diabetic and non-diabetic patients 
were determined using the EndoCult™ system (StemCell Technologies, 
USA) as described (see 3.2.4.3.). 
 
5.2.10.2 Migration assay  
 
See 4.2.4.5.  
 
5.2.11. Statistical analysis 
 
See 3.2.6. 
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5.3. Results  
 
5.3.1. Reduced numbers and impaired function of EPC from 
diabetic patients - evidence for eNOS uncoupling  
 
Diabetic patients were characterised by increased plasma glucose 
concentration (294.0±32.0 mg/dl vs 100.0±6.4 mg/dl) and increased HbA1c 
values (8.8%±0.6% vs 5.4%±0.1%) compared with non-diabetic age-matched 
subjects. Patient characteristics are shown in 5.4.1. (Table 1). 
Diabetic patients displayed reduced formation of endothelial CFUs compared 
with non-diabetics (9.8±1.9 CFUs vs 22.6±1.7 CFUs; p=0.001; see 5.5.1. 
(Fig. 1A, B)). A detailed description of human EPC characterisation has been 
previously published ((100); 5.5.1. (Fig. 1)). EPC from diabetic patients had 
increased ROS formation (11.7±0.7 vs. 6.2±1.1 arbitrary units; p<0.001; 
5.5.2. (Fig. 2A, 2B)) but impaired migratory capacity compared with EPC 
from non-diabetic age-matched subjects (40.4±4.6 vs. 72.7±6.2 migrated 
cells; p<0.0001; 5.5.2. (Fig. 2C)). After NOS inhibition with L-NNA in EPC 
from diabetic patients, ROS production was attenuated and cellular migration 
was improved by 34.6 % ± 5.6 % (p<0.05; 5.5.2. (Fig. 2A-2C)). Incubation of 
diabetic EPC with pegylated superoxide dismutase (SOD) completely 
inhibited ROS formation and improved migration by 60.1% ± 11.3 % 
(p<0.001; 5.5.1. (Fig. 2A-2C)).  
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5.3.2. Uncoupling of eNOS and ROS-mediated EPC dysfunction in 
cultured EPC by glucose treatment - effects of protein kinase C 
inhibition and tetrahydrobiopterin (BH4) treatment  
 
To test whether observations from the clinical study can be related to the 
increased glucose concentration in patients, further in vitro studies were 
performed. Glucose treatment increased ROS production up to 3-fold and 
impaired migratory capacity of cultured EPC by 55.7±8.2% (p<0.001), 
whereas treatment with mannitol (30mM) as osmotic control had no effect 
(5.5.3. (Fig. 3A, 3B)). Increased concentrations of O2- react with NO in a 
reaction forming peroxynitrite, the latter being a powerful toxicant to a wide 
range of cells. Peroxynitrite is difficult to measure and reacts quickly with a 
variety of different biomolecules to produce 3-nitrotyrosine. In glucose-
challenged EPC, 3-nitrotyrosine concentration was substantially higher than 
in controls, whereas NOS and to a lesser extent NADPH oxidase inhibition 
attenuated exaggerated 3-nitrotyrosine production (5.5.3. Fig. 3C)). 
Combined NOS and NADPH oxidase inhibition completely inhibited 3-
nitrotyrosine production in glucose-challenged EPC (5.5.3. (Fig. 3C)). 
 
The glucose-mediated impairment of EPC migration was diminished when 
cells were concomitantly treated with pegylated SOD (5.5.3. (Fig. 3B)). 
Inhibition of NOS with L-NNA attenuated the detrimental effects of glucose 
(5.5.3. (Fig. 3A, 3B)).  
 
As protein kinase C is involved in vascular O2- production in diabetic vessels 
(42) additional studies were performed to analyse its importance in glucose-
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mediated ROS production in EPC. Inhibition of PKC by chelerythrine 
attenuated O2- production after treatment of EPC with glucose. In parallel, 
EPC function was improved (5.5.3. (Fig. 3A, 3B)). PKC may also activate 
NADPH oxidases (154) and therefore additional tests with regard to the 
contribution of NADPH oxidases in glucose-mediated impairment of EPC 
were performed.  Inhibition of NADPH oxidases resulted in a slight reduction 
of intracellular O2- levels after glucose challenge, whereas combined 
inhibition of NOS and NADPH oxidases strongly lowered O2- production. A 
trend for improved migratory capacity was also observed after concomitant 
treatment with glucose and DPI, although this was not statistically significant. 
However, synergistic effects on the improvement of EPC migration after 
glucose challenge were observed after combined treatment with L-NNA and 
DPI (5.5.3. (Fig. 3)).  
 
In addition, a reduction of the essential eNOS cofactor BH4 has been 
described to be mechanistically involved in eNOS uncoupling (42; 148). 
Intracellular levels of BH4, total and oxidised biopterin levels were measured 
in lysates from glucose-challenged and control EPC. Glucose treatment 
significantly reduced the concentration of intracellular BH4 by 59%, whereas 
oxidised biopterin levels raised by 36% (p<0.05). Total biopterin levels were 
basically unchanged (5.5.4. (Fig. 4A, 4B)). To test whether reversal of the 
glucose-mediated reduction in intracellular BH4 levels would rescue EPC 
function we performed further studies. Exogenous treatment of glucose-
challenged EPC with BH4 increased its intracellular availability by 5-fold 
compared with untreated controls. As a result glucose-mediated exaggerated 
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O2- production was attenuated and EPC migratory capacity was significantly 
improved (5.5.4. Fig. 4C, 4D)). 
 
5.3.3. eNOS uncoupling in bone marrow in experimental diabetes 
mellitus – consequence for circulating EPC 
 
To understand whether reduced levels of EPC in diabetes are potentially 
mediated by changes of EPC-mobilising pathways in bone marrow, we used 
rats with streptozotozin-induced diabetes. Diabetic animals had higher serum 
glucose levels compared with control animals (459±39 mg/dl vs. 151±15 
mg/dl, p<0.0001). In contrast, levels of circulating EPC were reduced to 
39±5% compared with non-diabetic animals (p<0.05) (5.5.5. (Fig. 5A)). A 
detailed rat EPC characterisation has been previously published by our group 
(17).   
Diabetes was associated with increased O2- production in bone marrow 
(5.5.5. (Fig. 5B,C). eNOS protein expression was increased in bone marrow 
extracts of diabetic rats (5.5.5. (Fig. 5D)), whereas eNOS phosphorylation 
(5.5.5. (Fig. 5E)), as well as eNOS dimer/monomer ratio was reduced (5.5.5. 
(Fig. 5F)). NOS inhibition by L-NNA increased O2--mediated 
chemiluminescence in bone marrow extracts from controls, but decreased 
O2- levels in diabetic bone marrow indicating uncoupling of eNOS to be 
involved in exaggerated O2- production (5.5.5. (Fig. 5C)).  
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5.4. Tables 
5.4.1. Table 1 Patients characteristics  
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5.5. Figures 
 
5.5.1. Figure 1 
 
 
Circulating endothelial progenitor cells are reduced in diabetic patients. 
Number of endothelial CFU in diabetic patients (n=5) and non-diabetic controls 
(n=5) (A).  (B) shows a typical endothelial CFU. Characterisation of monocytic 
endothelial progenitor cells (labeled in red) based on their ability to migrate towards 
a VEGF/SDF-1 gradient (C) and to incorporate/adhere during vascular network 
formation on matrigel when co-cultured with human umbilical vein endothelial cells 
(labeled in green, D).   Expression of the vWF in EPC including formation of typical 
Weibel-Palade Bodies (intense green spots) (E). Figures E-H show vWF expression 
(E), Dil-acLDL uptake (F), nuclear staining by DAPI (G) and merged pictures (H). 
Data of endothelial CFU represent mean ± SEM.  
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5.5.2. Figure 2 
 
 
Uncoupling of eNOS leads to ROS-mediated EPC dysfunction in diabetic 
patients.  
FACS analysis demonstrating intracellular ROS levels (A, B) and migratory capacity 
(C) of isolated EPC from healthy controls and diabetic patients. A subgroup of EPC 
from diabetic patients was additionally pre-treated with superoxide dismutase (SOD) 
or NG-nitro-L-arginine (L-NNA).  * P<0.05, ** P<0.001, *** P<0.0001;  † P <0.0001 vs 
diabetic EPC. Data represent mean ± SEM. n=5 measurements per group. 
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5.5.3. Figure 3 
 
Glucose treatment leads to eNOS uncoupling and impaired migratory capacity 
of EPC.  A) Detection of fluorescent ethidium after staining of cultured EPC with the 
redox-sensitive, cell-permeable fluorophore dihydroethidium. B) Migratory capacity 
of EPC. EPC were treated with ascending doses of glucose, glucose + SOD, 
glucose + L-NNA, glucose + the protein kinase C inhibitor chelerythrine, glucose + 
the NADPH oxidase inhibitor DPI or mannitol. C) Free 3-nitrotyrosine levels in EPC 
lysates after treatment with glucose (24 h, 30mM).   
 * P<0.001, ** P<0.0001;  † P <0.05 vs glucose, 30mM; †† P <0.01 vs glucose, 
30mM; ††† P <0.0001 vs glucose, 30mM.  Data represent mean ± SEM. n=4-6 
measurements per study group. 
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5.5.4. Figure 4 
 
 
 
Tetrahydrobiopterin (BH4)-dependent rescue of glucose mediated EPC 
dysfunction  
Detection of intracellular BH4 levels (A), total biopterin (B), alkaline-stable oxidised 
biopterin (BH2 plus biopterin) (C), superoxide anions (D) and measurement of 
migratory capacity (E) of EPC. EPC were treated with glucose or glucose + BH4 
(10µM). Each n=4-6 experiments. * P<0.05, ** P<0.01, *** P<0.001; †† P <0.01 vs 
glucose, ††† P <0.001 vs glucose. Data represent mean ± SEM. 
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5.5.5. Figure 5 
 
 
 
Reduced circulating EPC and eNOS uncoupling in bone marrow in rats with 
STZ-induced diabetes. (A) Circulating endothelial progenitor cells. (n=6 controls; 
n=7 diabetic animals).  (B) Superoxide anion production in bone marrow extracts 
assessed by lucigenin (5µM) -enhanced chemiluminescence and (C) % of change 
after addition of L-NNA (1mmol/L). (D) eNOS protein expression and (E) eNOS 
phosphorylation as revealed by Western blot analysis. (F) eNOS dimer:monomer 
ratio. Control= control rats, n=7; Diabetes= rats with streptozotocin-induced 
diabetes, n=7.   † P<0.05, †† P <0.001 vs control. Data represent mean ± SEM. 
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5.6. Discussion  
 
In this part of the thesis, uncoupling of eNOS was demonstrated in EPC from 
diabetic patients, in glucose-treated EPC and in bone marrow from diabetic 
rats. eNOS uncoupling explains at least in part reduced levels and impaired 
function of EPC observed in diabetes and provides a possible 
pharmacological target. This is of importance, as diabetic patients are at high 
risk for endothelial lesions and arteriosclerosis and finally, as EPC essentially 
contribute to vascular lesion repair (155). 
 
Under physiological conditions, eNOS confers anti-arteriosclerotic vascular 
protection. Indeed, eNOS-deficient mice display enhanced onset and rapid 
progression of arteriosclerosis (156). Exogenous NO may reverse the 
migratory defect of EPC associated with diabetes (157). In general, 
increased eNOS expression is considered to be beneficial. However, under 
certain pathophysiological conditions up regulation of eNOS expression is 
associated with reduced endothelium-dependent vasodilatation (158-161) 
explained by the so-called ‘eNOS uncoupling’ (reviewed in (148; 160; 161). 
Under this condition eNOS itself can be a source of O2-, instead of NO (148). 
eNOS uncoupling was shown in a variety of experimental and clinical 
vascular disease states, especially in diabetes mellitus (43; 148; 162). 
Diabetes associated eNOS uncoupling has been described in the heart, 
vessels or the kidney (42; 158; 161; 163-166) resulting in decreased NO 
bioavailibility, increased superoxide production and disrupted eNOS dimer 
formation within the vascular wall, while eNOS mRNA and/or protein levels 
are maintained or even increased (163-165). A reduction of the essential 
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eNOS cofactor BH4 has been described to be mechanistically involved in 
eNOS uncoupling by various groups (148; 158; 164; 167). 
 
In the present study, EPC from diabetic patients displayed increased 
intracellular ROS levels, reduced endothelial CFU capacity, and impaired 
migratory function, which were improved after NOS inhibition. In vitro, high 
glucose concentration led to increased ROS production, 3-nitrotyrosine levels 
and impairment of EPC function in EPC. It should be pointed out that 
although the findings obtained in vivo and in vitro basically show the same 
effects on ROS formation and function of EPC, the in vitro assay is a highly 
artificial system. Whereas in vivo EPC are exposed to high glucose levels for 
a long time period, in vitro we only used 24h treatment of EPC with glucose. 
In addtion, several other known as well as unknown factors in the blood, that 
are stongly altered in diabetic patients, may have effects on EPC. Those 
factors were not investigated in vitro based on the culture conditions. 
However, it is highly likely that enhanced glucose levels both have short-term 
(in vitro) and/or long-term (in vivo) detrimental effects on EPC. 
While EPC are equipped with powerful antioxidative enzyme systems that 
may reduce the damaging effects of ROS (168), a direct correlation between 
functional capacity of EPC and intracellular ROS production has recently 
proposed (61; 169; 170). Glutathione peroxidase-1 deficient mice had 
increased ROS production and suffered from impaired migratory capacity of 
EPC and reduced angiogenesis in vitro (169). Likewise, oxidant stress 
impairs in vivo re-endothelialisation capacity of EPC from patients with mild 
forms of type 2 diabetes mellitus (60). This defect can be restored at least in 
part by the peroxisome proliferator-activated receptor-gamma agonist 
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rosiglitazone. In this study exessive ROS production was mainly mediated via 
enhanced NAPDH oxidase activity. A potential explanation for the partly 
discrepant findings with those of the thesis may be differences in the patient 
populations. Sorrentino et al. investigated type II diabetics with only slightly 
increased HbA1c levels (6.6±2.2%) without presentation of potential 
underlying anti-diabetic treatment including insulin, whereas we investigated 
EPC from untreated diabetic patients with a high HbA1c of 8.8±0.6%. 
Probably, activation of NADPH oxidase occurs early in diabetes and/or in 
mild diabetic forms (60), whereas eNOS uncoupling with an even stronger 
subsequent production of ROS predominantly exists in advanced diabetes.  
 
The protective role of eNOS may only be maintained under a 
normoglycaemic environment as under hyperglycaemic conditions eNOS has 
been shown to become uncoupled to produce O2- (42; 43; 148). Indeed, in 
chapter III and chapter IV we have shown that enhancement of eNOS 
expression by rosuvastatin or IGF-1 has beneficial effects on EPC function. It 
cannot be ruled out that molecules that increase eNOS expression, may 
have detrimental effects in a situation where eNOS is uncoupled (e.g. 
diabetes). Moreover, under those circumstances it may be that eNOS 
inhibiting substances such as ADMA may protect a cell from exaggerated 
eNOS-mediated ROS production, whereas statins or IGF-1 increase ROS 
formation. This needs to be tested in the future.  
Addition of superoxide dismutase, that highly efficiently detoxifies O2-, 
completely normalised ROS production and EPC function.  As NOS inhibition 
only partly attenuated O2- production, other systems may also be involved in 
ROS production and EPC dysfunction in a diabetic environment, such as 
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excessive mitochondrial production of ROS (169) or increased activation of 
the p38 MAP kinase in EPC (171). However, eNOS uncoupling in EPC as 
shown in the present part of the thesis seems to play an important and 
dominant role in glucose-mediated EPC dysfunction. 
 
The underlying molecular mechanisms by which increased ROS may disturb 
EPC function are unclear, but reduced bioavailability of NO or the eNOS 
cofactor BH4 may be involved (148; 156; 167). Indeed, intracellular BH4 levels 
depend by large on their degradation due to excessive oxidation (reviewed in 
(148)). Reduced BH4 levels have been reported in diabetic eNOS uncoupling 
(148; 158; 162), and restoration of BH4 levels can "re-couple" eNOS and 
enhance its regular enzymatic activity (148; 167). Here for the first time a 
critical role for intracellular BH4 levels for coupling and uncoupling of eNOS in 
EPC has been shown. Indeed, a significant reduction of intracellular BH4 
levels after challenging EPC with high concentrations of glucose was 
observed, whereas oxidised biopterin levels were significantly increased. 
This switch from BH4 levels to oxidised biopterin strengthens the present 
results that during glucose challenge eNOS in EPC becomes uncoupled. 
Strikingly, addition of exogenous BH4 resulted in reduction of intracellular O2- 
levels and complete rescue of EPC function during high dose glucose 
treatment.   
 
Protein kinase C is involved in the vascular O2- production in diabetic vessels 
(42). Its inhibition restores vascular NO bioavailability and endothelial 
function (42), but a role in EPC has not been investigated so far. This study 
shows PKC to be essential in translation of the detrimental effects of high 
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levels of glucose to EPC. PKC inhibition resulted in reduced glucose-
mediated O2- production and improvement of EPC function, suggesting a 
potential therapeutic role of PKC inhibitors in dysfunctional EPC.   
 
While reduced circulating EPC levels in diabetes have been observed in 
several human studies (10; 39; 172), alterations in EPC mobilising pathways 
within diabetic bone marrow have not been identified so far. A pivotal role for 
eNOS in the regulation of EPC mobilisation was shown with eNOS-deficient 
mice, which show impaired capacity to mobilise EPC and impaired function of 
isolated EPC (21). In the bone marrow, eNOS is the uniquely expressed NOS 
isoform, whereas iNOS or nNOS are not detected (173). In this study eNOS 
expression in the bone marrow of diabetic rats was elevated, but also eNOS 
monomerisation and superoxide anion production were increased. O2- 
production was blocked upon NOS inhibition. This alteration provide 
therefore evidence for eNOS uncoupling within bone marrow in diabetes. The 
uncoupling of eNOS has previously been linked to its monomerisation upon 
treatment of endothelial cells with peroxynitrite or glucose (164; 174). In 
diabetic bone marrow eNOS dimer/monomer ratio was shifted to 
monomerisation. Changes in the dimer/monomer ratio are not directly linked 
to functional uncoupling of eNOS, as only the dimeric form appears to be 
biochemically active and is able to generate either NO or O2-. However, the 
eNOS monomer can be viewed as a marker for eNOS uncoupling. eNOS 
uncoupling in bone marrow lowers NO bioavailability and thus likely 
contributed to the observed reduced levels of circulating EPC. 
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In conclusion, eNOS uncoupling impairs EPC number and function in 
diabetes, thus contributing to the pathogenesis of vascular disease. 
 
5.7. Limitations 
 
It cannot be ruled out that other O2--producing systems play additional roles 
in the observed effects especially during various stages of diabetes. For 
instance a minor contribution of NADPH oxidases was observed in glucose-
mediated increase in ROS formation and subsequent reduction in EPC 
function. However, a stronger attenuation of O2- formation was seen after 
eNOS inhibition indicating a major role for uncoupled eNOS in superoxide 
production in diabetes.  This also needs to be investigated in diabetes in vivo. 
 
Data on this part of the thesis have recently been published (63). 
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Chapter VI Overlapping and opposing findings- 
Importance of nitric oxide bioavailability 
 
6.1. Introduction 
 
Whereas the first part of this thesis investigated the effects of ADMA on EPC 
biology in patients with different severity levels of coronary artery disease 
(Chapter III), the follow-up studies focused on aging (Chapter IV) or type II 
diabetes (Chapter V). As in the patient group described in Chapter III 23.8% 
were diabetic, it is likely that the investigated mechanism of eNOS 
uncoupling in diabetic EPC (Chapter V) also contributed to EPC dysfunction 
in selected diabetic patients. Moreover, due to their role as NOS inhibitors, 
high ADMA levels in patients with enhanced and untreated diabetes might be 
rather protective than harmful, as the it may be that inhibition of uncoupled 
eNOS prevents exaggerated ROS production. This should to be investigated 
in future experimental and clinical studies. Likewise, the aged group of 
patients investigated in Chapter IV may also suffer from CAD, but this has 
not been examined in detail. ADMA levels were only investigated in the 
middle-aged patient population before and after growth hormone treatment 
(see Results section of this Chapter). It is also important to note that others 
have reported changes of ADMA levels during age (175), which could have 
contributed to the changes in EPC function in elderly individuals detailed in 
Chapter IV. Enhanced growth hormone and or IGF-1 levels may additionally 
influence levels of glucose and/or ADMA. Indeed, long-term GH treatment of 
healthy elderly more likely resulted in the onset of diabetes mellitus and 
impaired fasting glucose (176), whereas GH supplementation of patients with 
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GH deficiency did not change fasting glucose levels or insulin sensitivity 
(177). 
NO bioavailability is highly likely to change during CAD initiation and/or 
progression, as well as during aging and diabetes. We hypothesized that the 
effect of GH supplementation on EPC in middle-aged healthy volunteers was 
mediated by improved NO bioavailability including reduction of ADMA levels. 
Additional animal and cell culture experiments were performed to clarify 
whether enhanced NO bioavailability was mediated directly via GH or by GH-
mediated IGF-1 increase. Finally, in vitro and in vivo measurements were 
performed to study the effects of GH treatment on ADMA levels and 
regulation. 
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6.2. Methods 
6.2.1. Experimental Subjects 
See 4.2.1. and Table 1 (6.4.1.) 
6.2.2. Measurement of clinical parameters 
6.2.2.1. Nitrate and nitrite 
Nitrate and nitrite in plasma and urine were measured by gas 
chromatography-tandem mass spectrometry (GC-MS/MS) with use of stable 
isotope-labelled internal standards as described previously (13). Urinary 
nitrate and nitrite concentrations were related to urine creatinine levels. To 
ensure that the urinary nitrate and nitrite levels were not influenced by high 
dietary nitrate/nitrite intake, volunteers were instructed to avoid food 
containing high amounts of nitrate/nitrite.  
6.2.2.2. Determination of IGF-1 and IGFBP-3 levels 
IGF-1 levels were measured as descried in 4.2.2.  IGFBP-3 measurement 
was performed using a radio immune absorbent (RIA) assay (Mediagnost, 
Reutlingen, Germany). As described by the manufacturer a highly affine, 
polyclonal antibody specific to IGFBP-3 was used. There was no known 
cross reactivity with either IGFBP-1 nor IGFBP-2. 
 
6.2.2.3. Determination of 8-iso-PGF2α 
8-iso-PGF2α levels were quantified by a previously described fully validated 
GC-MS/MS method. Urinary excretion rates of 8-iso-PGF2α were corrected 
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for creatinine, which was determined spectrophotometrically by the alkaline 
picric acid reaction with an automatic analyzer (Beckmann 6641, Galway, 
Ireland). Samples were spiked with [2H4]-8-iso-PGF2α (Cayman, Ann Arbor, 
MI, USA) as an internal standard and acidified to pH 3.5. Analytes were solid-
phase extracted on octadecylsilica cartridges and eluted from the columns 
with ethyl acetate. After solvent evaporation, the pentafluorobenzyl esters 
were prepared, subsequently separated by thin-layer chromatography and 
further converted to their trimethylsilyl ether derivatives, and analyzed by GC-
MS/MS in the selected reaction mode exactly as described elsewhere (178). 
 
6.2.2.4. Determination of cGMP levels 
To quantify urinary cGMP levels an enzyme linked immuno sorbent assay 
(Sunrise, Tecan) was used. A known quantity of peroxidase-labelled cGMP 
was added to the probe. A cGMP specific antibody was immobilized by a 
secondary antibody to a microtiter plate. After binding of the free cGMP to the 
plate, the remaining free cGMP was washed off and the bound 
cGMP/peroxidase labelled cGMP could be detected by adding 3,3’, 5,5’- 
tetramethylbenzene. The reaction product was quantified by photometry at 
450 nm in an ELISA reader. In case of the mouse study, cGMP was 
measured using a cGMP enzyme immunoassay (Amersham Biosciences, 
USA) according to the manufacturer’s instructions.  
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6.2.2.5. Determination of ADMA and DMA levels 
In case of the human studies measurement of ADMA was performed by a 
combined gas chromatograph / mass spectrometer based method (100). 
ADMA plasma levels of mice were determined by a commercial available 
ADMA-ELISA kit (DLD Diagnostika GmbH, Germany). Dimethylamine (DMA) 
levels were analyzed as described previously (179). 
 
6.2.2.6. Determination of basic blood parameters and VEGF  
Basic blood parameters were accessed by standard laboratory 
measurements (Medical School Hannover, Germany) and VEGF levels were 
measured by a commercial ELISA kit (R&D Systems, Germany) according to 
the manufacturer’s recommendation. 
 
6.2.3. Determination of endothelial progenitor cells  
We isolated and quantified both CD133+/VEGFR2+ EPC and endothelial 
colony forming units (CFU) as described (4.2.4.2. and 3.2.4.3.). 
 
6.2.4. Human endothelial cell culture experiments and expression 
of DDAH1/2 in response to IGF-1  
Human umbilical vein endothelial cells (HUVEC) and human coronary arterial 
endothelial cells (HCAECs) were cultured until sub-confluence as described 
(180) and then treated with IGF-1 (100nM) for 24h. Timing and 
concentrations were based on a previous study (62). Untreated cells served 
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as controls. Total RNA isolation, RT-PCR experiments and data analysis 
were performed as described (62). PCR experiments were done within the 
log-linear range of amplification. DDAH1/2 primer sequence information were 
obtained from Monsalve et al. (181). 
6.2.5. Experimental Animals 
The animal studies conform to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). Details about treatment was previously shown (see 
4.2.12.). After treatment we determined plasma cGMP and ADMA as 
markers for systemic NO availability. eNOS protein expression was 
investigated by Western blotting experiments of total protein lysates of aortic 
tissue of treated mice as described (17).  
 
6.2.6. Statistical methods 
Data are expressed as mean±SEM. Statistical analysis was performed by 
one-way ANOVA or paired T-test followed by multiple comparisons using 
Fisher’s protected least-significant difference test. To analyze relationships 
between variables simple and multivariate regression analyses were 
performed. Statistical analysis was performed using StatView 5.0 statistic 
program (Abacus Concepts, Berkley, CA, USA). Statistical significance was 
assumed at P<0.05. 
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6.3. Results 
6.3.1. Clinical study 
 
6.3.1.1. Alterations of basic cardiovascular parameters 
All volunteers completed the study in accordance with the study protocol and 
no serious adverse events were observed. Diastolic blood pressure was 
moderately, but significantly reduced (86.7+1.7 vs. 83.3+1.7 mmHg, p<0.05), 
whereas systolic blood pressure remained basically unchanged (133.3+3.7 
vs. 131.0+2.9 mmHg, p=0.2). No change of heart rate (63.2+1.9 vs. 65.3+2.1 
beats per minute, p=0.2) could be detected. 
 
6.3.1.2. Growth hormone-mediated changes in basic blood 
parameters 
A ten day supplementation of healthy middle-aged volunteers with GH 
significantly raised IGF-1 (126 + 8.0 vs. 231.3 + 9.59 in ng/ml, p<0.0001) as 
well as IGF-binding protein 3 (IGFBP-3) plasma levels (2.49 + 0.30 vs. 3.12 + 
0.12 mg/l, p<0.005) (see 6.5.1.; Fig. 1 A,B). No significant changes were 
found in total cholesterol, HDL-cholesterol, LDL-cholesterol or triglyceride 
plasma levels. Likewise, haemoglobin, erythrocyte, leukocyte and 
homocysteine levels remained unaffected (see 6.4.2.; Table 2).  
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6.3.1.3. Changes and correlations of markers of NO bioavailability 
with circulating endothelial progenitor cells 
As markers for NO bioavailability we measured nitrate and nitrite (NOx) 
levels in plasma and in urine, cGMP, ADMA and DMA levels as well as 8-iso-
PGF2α (marker for oxidative stress). Plasma ADMA levels were reduced 
(0.55 + 0.02 vs. 0.52 + 0.02 µM, p<0.05), whereas cGMP levels were 
significantly increased (12.5 + 1.1 vs. 14.8 + 1.1 µmol/mmol creatinine, 
P<0.05) after GH supplementation (see 6.5.1.; Fig. 1C). IGF-1 correlated 
significantly with urinary cGMP levels (6.5.1.; Fig. 1D). Reduction of plasma 
ADMA levels was independent from plasma NOx levels as well as from 
diastolic or systolic blood pressure. Urinary ADMA levels were unchanged 
(3.3 + 0.2 vs. 3.5 + 0.2 µmol/mmol creatinine) but were positively correlated 
with urine NOx (p<0.05). Diastolic blood pressure was closely correlated with 
NOx plasma levels (p<0.05) (6.5.1.; Fig. 1E). 8-iso-PGF2α as a marker for 
oxidative stress was not significantly changed (6.4.2.; Table 2). VEGF levels 
tended to be increased (6.4.2.; Table 2) after GH supplementation. 
Circulating EPC levels were significantly increased (both CD133+/VEGFR2+ 
cells and CFUs), closely related with IGF-1 levels (see 6.5.2.; Fig. 2 A,B) and 
borderline correlated with VEGF levels (p=0.06; see 6.5.1.; Fig. 2C). In 
addition, we performed a stepwise multivariate regression analysis and found 
IGF-1 (standardized coefficient 0.78, p<0.01) and urinary nitrite as marker for 
NO (standardized coefficient 0.56, p<0.001) to be independently related to 
the number of circulating CD133+/VEGFR2+ progenitor cells.  
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6.3.2. Animal studies 
 
6.3.2.1. Increased NO bioavailability in response to growth 
hormone is IGF-1 dependent 
To test whether GH supplementation directly or via subsequent IGF-1-
mediated increase improves NO bioavailability, we performed further studies 
in mice. GH treatment for 7 days, but not 2 days increased IGF-1 plasma 
levels (controls: 229.7±19.2 ng/ml; GH application for 2 days: 241.4±1.4 
ng/ml; p=non significant; GH application for 7 days: 489.6±96.6 ng/ml; 
p<0.01). Likewise, a 2 day treatment with IGF-1 increased systemic IGF-1 
plasma levels by 3-fold (654.7±64.8; p<0.0001).  
cGMP levels were increased after a 7 day treatment  (1479+111 vs. 
2343+407 fmol/well; p<0.05) or after treatment with IGF-1 (2182±315 
fmol/well; p<0.05). Aortic eNOS expression was significantly increased by 
30% after GH (7d) treatment (see 6.5.4.; Fig. 4). In contrast, ADMA levels 
were decreased after GH treatment for 7 days (0.89+0.03 vs. 0.76+0.03 
µmol/l; p<0.05) as well as after IGF-1 treatment (0.76+0.01 µmol/l; p<0.05). 
In contrast short GH treatment for only 2 days did not alter cGMP or ADMA 
plasma levels.  Blocking of IGF-1/IGF1-receptor signalling cascade in vivo by 
a specific small molecule inhibitor of the IGF-1 receptor completely abolished 
the effects of GH treatment on the latter markers of NO bioavailability (see 
6.5.3; Fig. 3A,B and 6.5.4; Fig. 4). Treatment of human HCAECs with IGF-1 
for 24h resulted in a significant increase in DDAH1 and DDAH2 expression 
(see 6.5.5; Fig. 5), whereas HUVECs were only partly responsive to IGF-1 
treatment. 
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We then correlated the amount of circulating EPC (sca-1+/flk1+ cells; see 
Chapter IV) with levels of systemic NO bioavailability, e.g. cGMP and ADMA 
plasma levels. Indeed, EPC numbers were positively correlated with cGMP 
(r=0.84; p<0.0001), but inversely correlated with ADMA plasma levels (r=-
0.45; p<0.05) (see 6.5.3; Fig. 3 C,D). 
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6.4. Tables 
6.4.1. Table 1  
 
In- and exclusion criteria for volunteers in the growth hormone study 
1. Inclusion criteria 
- Healthy male subjects without recent severe disease  
- Age > 50 yrs  
- BMI < 30 kg/m2 
- Personally signed and dated informed consent document indicating that the 
subject has  been informed of all pertinent aspects of the trial 
- Subjects that were willing and able to comply with scheduled visits, treatment 
plan, laboratory tests and  other study procedures 
2. Exclusion criteria 
- History of any severe hepatic, renal, cardiac, endocrine, metabolic, or 
malignant disease 
- Requirement for medical drug treatment 
- GH treatment during the last 12 months 
- Drug dependence, alcohol or nicotine abuse 
- Other severe acute or chronic medical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or 
may interfere with the interpretation of study results and, in the judgment of 
the investigator, made the subject inappropriate for entry into this study. 
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6.4.2. Table 2 
 
Response of middle-aged volunteers to growth hormone treatment 
 before GH 
treatment 
after GH 
treatment 
P value 
 
IGF-1/IGFBP3 levels    
IGF-1 [ng/ml] 126.0 + 8.0 231.3  + 9.6 P<0.0001 
IGFBP-3 [mg/l] 2.5 + 0.3 3.1 + 0.1 P<0.005 
Cardiovascular parameters    
heart rate [beats/min] 63.2 + 1.9 65.3 +2.05 P=0.2 
systolic blood pressure[mmHg] 133.3 +14.75 131.0 + 2.8 P=0.2 
diastolic blood pressure [mmHg] 86.7 + 1.7 83.3 + 1.7 P<0.05 
Basic blood parameters    
total cholesterol [mg/dl] 217.3  + 9.7 212,3  + 9.8 P=0.5 
LDL-cholesterol [mg/dl] 127.1 + 8.3 124.7  + 8.3 P=0.6 
HDL-cholesterol [mg/dl] 58.0 + 4.6 56.1  + 4.8 P=0.2 
triglycerides [U/l] 98.0 + 12.7 114.0 + 12.4 P=0.3 
hemoglobin [g/dl] 14.6 + 0.2 14.5 + 0.2 P=0.2 
erythrocytes [x106/µl] 4.8 + 0.1 4.8 + 0.1 P=0.6 
leukocytes [x103/ml] 5.1 + 0.3 5.1 + 0.3 P=0.95 
homocysteine [µM] 7.8 + 0.6 7.6 + 0.5 P=0.9 
8-iso-PGF2α [nM/mM creatinine] 55.2 + 5.6 60.1 + 6.1 P=0.08 
Marker for NO availability    
cGMP [µM/mM creatinine] 12.5 + 1.1 14.8 + 1.1 P<0.05 
NOx (urine) [µM/mM creatinine] 92.7 + 8.1 100.7 + 9.4 P=0.5 
NOx (plasma) [µM/l] 31.9 + 1.9 33.7 + 3.3 P=0.6 
ADMA (plasma) [µM] 0.55 + 0.02 0.52 + 0.02 P<0.05 
ADMA (urine) [µM/mM creatinine] 3.3 + 0.2 3.5 + 0.2 P=0.2 
DMA [µM/mmol creatinine] 34.0 + 2.9 32.1 + 1.5 P=0.5 
VEGF [pg/ml] 19.3 + 1.1 20.6 + 1.2 P=0.4 
Endothelial progenitor cells    
CFU [per well] 14.1 + 1.5 22.1 + 1.6 P<0.0001 
CD133+/VEGFR2+ cells [% of MNCs] 0.004 + 0.0004 0.008 + 0.0012 P<0.01 
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6.5. Figures 
6.5.1. Figure 1 
 
 
 
Insulin-like growth factor-1 (IGF-1) (A), IGF-1 binding protein-3 (IGFBP-3) (B), 
urinary cGMP/creatinine levels (C) and correlations of ÍGF-1 and urinary 
cGMP/creatinine (D) as well as of plasma nitrate/nitrite (NOx) levels with diastolic 
blood pressure (E) in healthy middle-aged volunteers before and after a 10 day 
treatment with recombinant human growth hormone (daily 0.4 mg). 
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6.5.2. Figure 2 
 
 
 
Simple regression analysis between IGF-1 plasma levels and endothelial colony 
forming units (CFU) (A) or circulating CD133+/vascular endothelial growth factor 
receptor-2(VEGFR2+) cells (B) in healthy middle-aged volunteers. Correlation 
between plasma VEGF levels and endothelial CFU (C). 
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6.5.3. Figure 3 
 
 
 
Markers of NO bioavailability in mice treated with growth hormone (GH, 2 or 7 days), 
GH and an IGF-1 receptor inhibitor or IGF-1 alone. cGMP levels (A) and ADMA 
levels (B) after different treatments are shown. Correlation of circulating EPC (sca-
1+/flk-1+ cells) with plasma levels of cGMP (C) and ADMA (D). 
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6.5.4. Figure 4 
 
 
Protein expression of eNOS in aortae of mice treated with placebo, GH (7d) or GH 
and an IGF-1 receptor inhibitor (n=5-6 per group).  
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6.5.5. Figure 5 
 
 
 
DDAH1, DDAH2 and GAPDH mRNA expression in cultured HUVEC and HCAECs 
treated with IGF-1 (100nM, 24h; each n=4). 
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6.6. Discussion 
 
This study provides evidence that IGF-1 mediates the increase in systemic 
NO bioavailability induced by growth hormone supplementation in vivo. In 
healthy middle-aged volunteers a short supplementation period of ten days 
with GH was sufficient to modulate several markers for increased systemic 
NO levels, e.g. elevation of the major NO downstream messenger cGMP and 
decrease of the endogenous NOS inhibitor ADMA. IGF-1 levels were 
correlated with cGMP levels pointing to a causal relationship. This was 
proved in an animal model using IGF-1 receptor blockade suggesting that 
IGF-1 is mainly responsible for the regulation of NO bioavailability by GH 
treatment in vivo.  
 
Evidence for IGF-1 to regulate NOS activity stems from various in vitro 
studies (124; 182).  
IGF-1 interacts with a tyrosine kinase membrane receptor that activates the 
phosphoinositide 3-kinase and serine/threonine kinase Akt signaling pathway 
facilitating eNOS expression and activity (125). Clinical studies have 
demonstrated that GH deficient patients display endothelial dysfunction and 
are at increased cardiovascular risk (115; 183; 184). GH supplementation of 
GH-deficient patients resulted in significant reductions in total peripheral 
resistance via increased NO bioavailability (115; 184; 185). Likewise, patients 
with chronic heart failure are characterized by impaired NO-dependent 
vasodilation, and GH substitution significantly improved NO production and 
vascular dysfunction (141). It was assumed that the improved NO 
bioavailability in response to GH is mediated by IGF-1. However, no direct 
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proof has so far been put forward. We here provide evidence that in vivo IGF-
1 is the major stimulus for an increase in NO availability after GH 
supplementation for the following reasons; firstly, IGF-1 and cGMP levels 
significantly correlated in volunteers after GH treatment; secondly, short-term 
treatment of mice with GH for only 2 days was not sufficient to increase IGF-
1 levels nor altered markers for NO. In contrast, a longer GH treatment 
period of 7 days significantly raised IGF-1 and cGMP levels, increased aortic 
eNOS protein expression and decreased the circulating endogenous NOS 
inhibitor ADMA. Thirdly, direct treatment of animals with recombinant IGF-1 
improved markers of NO availability. Lastly, and most importantly, blocking 
the IGF-1/IGF-1 receptor signalling cascade by a small molecule inhibitor of 
the IGF-1 receptor (109) completely prevented the GH-mediated changes in 
cGMP and ADMA plasma levels, as well as aortic eNOS expression.  
 
The alterations in systemic NO availability likely influence EPC biology. EPC 
contribute to adult vessel formation, and injection of EPC improved vascular 
function, blood flow in ischemic tissue, and heart function (7; 56; 186). NO 
does not only play a major role in the release of EPC from bone marrow but 
also improves EPC function and migration capacity (17; 21; 22; 62). 
Likewise, the vascular endothelial growth factor (VEGF) is partly involved 
during the process of EPC mobilisation, recruitment and overall 
neovascularisation (21). Interestingly in our study both markers of NO 
availability and VEGF plasma levels were correlated with the amount of 
circulating EPC.  
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In contrast, the endogenous NO synthase inhibitor ADMA has negative 
effects on number, function and migration capacity of EPC (100). ADMA is a 
strong and independent predictor of mortality and cardiovascular outcome 
and is correlated with endothelial dysfunction in systemic cardiovascular 
diseases (26; 77; 187). Supplementation of both healthy volunteers and mice 
with growth hormone resulted in modest, but significant reductions of plasma 
ADMA levels probably due to the IGF-1-mediated induction in endothelial 
DDAH1/2 expression. The overall improved NO bioavailability may contribute 
to the rise in EPC levels after GH therapy as shown recently (62).  A positive 
effect on circulating EPC levels by GH supplementation could be of 
advantage in the treatment of cardiovascular diseases with impaired number 
of EPC, such as coronary artery disease (9; 100). This may particular apply 
for GH deficient patients due to advanced age or other primary or secondary 
causes.  
 
Although the correlations between systemic NO markers and EPC levels 
does not prove a direct cause/effect relationship, they are suggestive for that. 
Our findings also indicate that circulating EPC levels may be a useful 
biosensor for the general NO bioavailability in an individual. Indeed clinical 
and animal data have shown, that drugs which improve NO bioavailability 
such as statins also increase circulating EPC levels (17; 22; 99), whereas 
patients with high amounts of plasma NOS inhibiting ADMA and low NO 
bioavailability display diminished circulating EPC numbers (100). Further 
studies should test the potential diagnostic and prognostic use of EPC 
number and function as a surrogate marker for overall NO bioavailability. 
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In conclusion, GH therapy improves markers of NO bioavailability and 
circulating EPC levels via IGF-1. Our initial pilot results warrant further and 
larger placebo-controlled studies that examine the potential vasoprotective 
effects of GH and/or IGF-1 as well as clinical outcome of treated patients with 
endothelial dysfunction and/or atherosclerosis including coronary artery 
disease.   
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Chapter VII Conclusions 
 
Endothelial progenitor cells are a circulating cell population participating in 
angiogenesis and vascular homeostasis. These cells are of fundamental 
importance as (re)vascularisation is essential for the survival of growing, 
injured or ischemic tissues. EPC numbers also have prognostic importance: 
patients with reduced EPC levels are at increased risk for cardiovascular 
events and death (14; 15), and circulating EPC correlate with enhanced 
coronary collateral development (16). However, as shown in this thesis, 
functional properties of EPC may be of equal or probably greater importance 
than quantitative alterations. Future studies should evaluate the potential of 
various EPC functions as predictors of future cardiovascular events. 
Functional limitations of progenitor cells from patients with CAD were first 
shown in 2004 (13). Consequently, treatment of CAD patients after 
myocardial infarction with autologous (dysfunctional) progenitor cells to 
improve neovascularisation and heart function may be ineffective. 
Identification of the mechanisms underlying EPC dysfunction in various 
diseases and patient populations as well as developing treatments for 
dysfunctional EPC will remain important tasks in future cardiovascular 
medicine. 
 
An aim of the present thesis was to investigate number and function of EPC 
in patients with common cardiovascular risk factors, such as high ADMA 
plasma levels (Chapter III), type II diabetes (Chapter V), or patients with 
advanced age (Chapter IV). EPC dysfunction was identified in all cases. 
However, the underlying molecular mechanisms were different; in patients 
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with CAD, in whom enhanced ADMA levels exerted inhibitory action on the 
eNOS expression in EPC resulting in low NO bioavailability. EPC from 
patients with advanced age had impaired telomerase activity and low eNOS 
expression contributing to cellular dysfunction. Finally, in patients with 
advanced type II diabetes, enhanced tetrahydrobiopterin oxidation and 
uncoupling of eNOS were identified leading to exaggerated intracellular 
superoxide anion production and EPC dysfunction. As outlined in Chapter VI 
it is likely that multiple mechanisms, but not a single mechanism may lead to 
alterations in EPC functions in various patients. 
 
Due to the various underlying mechanistic impairments, it was necessary to 
develop different treatment approaches; Drugs that increase eNOS 
expression, such as statins, were able to normalise ADMA-mediated 
impairment of EPC (Chapter III). In patients with advanced age low EPC 
levels and impaired EPC function were improved by growth hormone– 
mediated increase of IGF-1. Whether this treatment approach would prevent 
further progression of atherosclerotic lesions by an activation of the 
endogenous EPC pool is currently speculative and more studies need to be 
performed (Chapter IV). Glucose-mediated EPC dysfunction could be 
rescued by PKC inhibition and tetrahydrobiopterin supplementation 
normalised glucose-mediated EPC dysfunction in vitro. Drugs targeting re-
coupling of uncoupled eNOS in diabetic patients therefore may be successful 
in prevention of endothelial dysfunction and development of severe 
atherosclerosis (Chapter V).  In contrast, enhancing expression of uncoupled 
eNOS may be detrimental.  
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After years of mainly descriptive research, in-depth mechanistic analysis has 
now begun to decipher the molecular causes of EPC dysfunction in various 
disease settings. In general, NO and superoxide producing enzyme systems 
may be valuable drug targets to optimise cellular NO bioavailability and to 
improve EPC function. However, different diseases may require different 
therapeutic approaches (e.g. eNOS uncoupling and low tetrahydrobiopterin 
levels in diabetes versus reduced eNOS levels in coronary artery disease or 
advanced age). The results of the present thesis may provide clues for the 
development of novel therapies for prevention and treatment of various 
cardiovascular diseases.  
 130
 
7.1. Summary scheme 
 
 
 
Contributing factors to endothelial progenitor cell dysfunction
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